<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="prp270078" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="iso-abbrev">Pharmacol Res Perspect</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2052-1707</journal-id><journal-id journal-id-type="publisher-id">PRP2</journal-id><journal-title-group><journal-title>Pharmacology Research &#x00026; Perspectives</journal-title></journal-title-group><issn pub-type="epub">2052-1707</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40001198</article-id><article-id pub-id-type="pmc">PMC11860274</article-id><article-id pub-id-type="doi">10.1002/prp2.70078</article-id><article-id pub-id-type="publisher-id">PRP270078</article-id><article-id pub-id-type="other">PRP2-2024-06-0204.R2</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>In Vitro Signaling Properties of Cannabinoid and Orexin Receptors: How Orexin Receptors Influence Cannabinoid Receptor&#x02010;Mediated Signaling</article-title></title-group><contrib-group><contrib id="prp270078-cr-0001" contrib-type="author"><name><surname>Mohamed</surname><given-names>Kawthar A.</given-names></name><xref rid="prp270078-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="prp270078-cr-0002" contrib-type="author" corresp="yes"><name><surname>Laprairie</surname><given-names>Robert B.</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9994-433X</contrib-id><xref rid="prp270078-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="prp270078-aff-0002" ref-type="aff">
<sup>2</sup>
</xref><address><email>robert.laprairie@usask.ca</email></address></contrib></contrib-group><aff id="prp270078-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">College of Pharmacy and Nutrition</named-content>
<institution>University of Saskatchewan</institution>
<city>Saskatoon</city>
<named-content content-type="country-part">Saskatchewan</named-content>
<country country="CA">Canada</country>
</aff><aff id="prp270078-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Pharmacology, Faculty of Medicine</named-content>
<institution>Dalhousie University</institution>
<city>Halifax</city>
<named-content content-type="country-part">Nova Scotia</named-content>
<country country="CA">Canada</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence:</bold>
<break/>
Robert B. Laprairie (<email>robert.laprairie@usask.ca</email>)<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>13</volume><issue seq="48">2</issue><issue-id pub-id-type="doi">10.1002/prp2.v13.2</issue-id><elocation-id>e70078</elocation-id><history>
<date date-type="rev-recd"><day>26</day><month>1</month><year>2025</year></date>
<date date-type="received"><day>07</day><month>6</month><year>2024</year></date>
<date date-type="accepted"><day>04</day><month>2</month><year>2025</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics--><copyright-statement content-type="article-copyright">&#x000a9; 2025 The Author(s). <italic toggle="yes">Pharmacology Research &#x00026; Perspectives</italic> published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley &#x00026; Sons Ltd.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:PRP2-13-e70078.pdf"/><abstract><title>ABSTRACT</title><p>The co&#x02010;expression of different types of G protein&#x02010;coupled receptors (GPCRs) in the same cells can have implications for receptor signaling and receptor cross&#x02010;talk, potentially altering the apparent potency or efficacy of ligands targeting each receptor. The endocannabinoid and orexinergic systems, consisting of class A GPCRs and their endogenous ligands, are highly complex and regulate processes such as appetite, sleep, nociception, and energy homeostasis. The shared anatomical distribution of cannabinoid and orexin receptors in various regions of the central nervous system (CNS), coupled with data from previous studies exploring physical and functional interactions between these receptors, suggests that the endocannabinoid and orexinergic systems engage in crosstalk. In this study, we explored how orexin receptors (OX<sub>1</sub>, OX<sub>2</sub>) altered the in&#x000a0;vitro signaling of cannabinoid receptors (CB<sub>1</sub>, CB<sub>2</sub>) in Chinese hamster ovary (CHO)&#x02010;K1 cells by quantifying cyclic adenosine monophosphate (cAMP) inhibition and &#x003b2;arrestin2 recruitment. Our results suggest that orexin receptors alter agonist&#x02010;dependent signaling at the cannabinoid receptors by enhancing cannabinoid receptor&#x02010;mediated cAMP inhibition while increasing or decreasing cannabinoid receptor&#x02010;mediated &#x003b2;arrestin2 recruitment. These initial results are important for understanding the effects associated with cannabinoid ligands and may provide novel insights for therapeutics targeting physiological processes modulated by both systems.</p></abstract><abstract abstract-type="graphical"><p>
<boxed-text position="anchor" content-type="graphic" id="prp270078-blkfxd-0001"><graphic xlink:href="PRP2-13-e70078-g004.jpg" position="anchor" id="jats-graphic-1"/></boxed-text>
</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="prp270078-kwd-0001">cAMP</kwd><kwd id="prp270078-kwd-0002">cannabinoid receptors</kwd><kwd id="prp270078-kwd-0003">cell signaling</kwd><kwd id="prp270078-kwd-0004">orexin receptors</kwd><kwd id="prp270078-kwd-0005">&#x003b2;arrestin2</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source><institution-wrap><institution>Natural Sciences and Engineering Research Council of Canada
</institution><institution-id institution-id-type="doi">10.13039/501100000038</institution-id></institution-wrap></funding-source><award-id>DGECR&#x02010;2019&#x02010;00207</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="4"/><page-count count="14"/><word-count count="9800"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:25.02.2025</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="prp270078-ntgp-0001"><fn fn-type="funding" id="prp270078-note-0001"><p>
<bold>Funding:</bold> This work was supported by Natural Sciences and Engineering Research Council of Canada, DGECR&#x02010;2019&#x02010;00207, NSERC Graduate Award.</p></fn></fn-group></notes></front><body id="prp270078-body-0001"><def-list list-content="abbreviations" id="prp270078-dl-0001"><title>Abbreviations</title><def-item><term id="prp270078-li-0001">2&#x02010;AG</term><def id="prp270078-li-0002"><p>2&#x02010;arachidonoylglycerol</p></def></def-item><def-item><term id="prp270078-li-0003">ANOVA</term><def id="prp270078-li-0004"><p>analysis of variance</p></def></def-item><def-item><term id="prp270078-li-0005">BRET</term><def id="prp270078-li-0006"><p>bioluminescence resonance energy transfer</p></def></def-item><def-item><term id="prp270078-li-0007">CB<sub>1</sub>
</term><def id="prp270078-li-0008"><p>type 1 cannabinoid receptor</p></def></def-item><def-item><term id="prp270078-li-0009">CB<sub>2</sub>
</term><def id="prp270078-li-0010"><p>type 2 cannabinoid receptor</p></def></def-item><def-item><term id="prp270078-li-0011">CHO</term><def id="prp270078-li-0012"><p>Chinese hamster ovary</p></def></def-item><def-item><term id="prp270078-li-0013">CI</term><def id="prp270078-li-0014"><p>confidence interval</p></def></def-item><def-item><term id="prp270078-li-0015">CNS</term><def id="prp270078-li-0016"><p>central nervous system</p></def></def-item><def-item><term id="prp270078-li-0017">CRC</term><def id="prp270078-li-0018"><p>concentration&#x02010;response curve</p></def></def-item><def-item><term id="prp270078-li-0019">DAG</term><def id="prp270078-li-0020"><p>diacylglycerol</p></def></def-item><def-item><term id="prp270078-li-0021">DAGL</term><def id="prp270078-li-0022"><p>diacylglycerol lipase</p></def></def-item><def-item><term id="prp270078-li-0023">DMEM</term><def id="prp270078-li-0024"><p>Dulbecco's Modified Eagle Medium</p></def></def-item><def-item><term id="prp270078-li-0025">DMSO</term><def id="prp270078-li-0026"><p>dimethyl sulfoxide</p></def></def-item><def-item><term id="prp270078-li-0027">DORA</term><def id="prp270078-li-0028"><p>dual orexin receptor antagonist</p></def></def-item><def-item><term id="prp270078-li-0029">EA</term><def id="prp270078-li-0030"><p>enzyme acceptor</p></def></def-item><def-item><term id="prp270078-li-0031">ECS</term><def id="prp270078-li-0032"><p>endocannabinoid system</p></def></def-item><def-item><term id="prp270078-li-0033">ED</term><def id="prp270078-li-0034"><p>enzyme donor</p></def></def-item><def-item><term id="prp270078-li-0035">EFC</term><def id="prp270078-li-0036"><p>enzyme fragment complementation</p></def></def-item><def-item><term id="prp270078-li-0037">eGFP</term><def id="prp270078-li-0038"><p>enhanced green fluorescent protein</p></def></def-item><def-item><term id="prp270078-li-0039">FBS</term><def id="prp270078-li-0040"><p>fetal bovine serum</p></def></def-item><def-item><term id="prp270078-li-0041">FRET</term><def id="prp270078-li-0042"><p>fluorescence resonance energy transfer</p></def></def-item><def-item><term id="prp270078-li-0043">FSK</term><def id="prp270078-li-0044"><p>forskolin</p></def></def-item><def-item><term id="prp270078-li-0045">GPCR</term><def id="prp270078-li-0046"><p>G protein&#x02010;coupled receptor</p></def></def-item><def-item><term id="prp270078-li-0047">IP3</term><def id="prp270078-li-0048"><p>inositol trisphosphate</p></def></def-item><def-item><term id="prp270078-li-0049">MAPK</term><def id="prp270078-li-0050"><p>mitogen&#x02010;activated protein kinase</p></def></def-item><def-item><term id="prp270078-li-0051">n.c.</term><def id="prp270078-li-0052"><p>not converged</p></def></def-item><def-item><term id="prp270078-li-0053">OX<sub>1</sub>
</term><def id="prp270078-li-0054"><p>orexin receptor type 1</p></def></def-item><def-item><term id="prp270078-li-0055">OX<sub>2</sub>
</term><def id="prp270078-li-0056"><p>orexin receptor type 2</p></def></def-item><def-item><term id="prp270078-li-0057">OXA</term><def id="prp270078-li-0058"><p>orexin A</p></def></def-item><def-item><term id="prp270078-li-0059">OXB</term><def id="prp270078-li-0060"><p>orexin B</p></def></def-item><def-item><term id="prp270078-li-0061">PBS</term><def id="prp270078-li-0062"><p>phosphate&#x02010;buffered saline</p></def></def-item><def-item><term id="prp270078-li-0063">Pen/Strep</term><def id="prp270078-li-0064"><p>penicillin&#x02013;streptomycin</p></def></def-item><def-item><term id="prp270078-li-0065">PLC</term><def id="prp270078-li-0066"><p>phospholipase C</p></def></def-item></def-list><sec id="prp270078-sec-0001"><label>1</label><title>Introduction</title><p>G protein&#x02010;coupled receptors (GPCRs) play a critical role in cellular signaling, converting various external stimuli (e.g., photons, ions, odorants, hormones, and neurotransmitters) into intracellular responses [<xref rid="prp270078-bib-0001" ref-type="bibr">1</xref>, <xref rid="prp270078-bib-0002" ref-type="bibr">2</xref>]. It has previously been demonstrated that GPCRs can interact with each other physically through receptor dimerization, a process that may involve two identical receptors (i.e., homodimers) or two distinct receptors (i.e., heterodimers) or indirectly via their convergent signal transduction pathways [<xref rid="prp270078-bib-0003" ref-type="bibr">3</xref>, <xref rid="prp270078-bib-0004" ref-type="bibr">4</xref>, <xref rid="prp270078-bib-0005" ref-type="bibr">5</xref>]. Ligand binding, receptor signaling, and receptor trafficking may be altered as a result of these GPCR interactions when receptors are co&#x02010;expressed in the same cells [<xref rid="prp270078-bib-0006" ref-type="bibr">6</xref>, <xref rid="prp270078-bib-0007" ref-type="bibr">7</xref>].</p><p>The endocannabinoid system (ECS) and orexinergic system are highly complex biological systems that regulate key physiological processes. Within the ECS, endogenous cannabinoids (endocannabinoids) are synthesized &#x0201c;on demand&#x0201d; from cell membrane lipids and activate a pair of GPCRs, namely the type 1 and type 2 cannabinoid receptors (<ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=56" ext-link-type="uri">CB<sub>1</sub>
</ext-link> and <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=57" ext-link-type="uri">CB<sub>2</sub>
</ext-link>, respectively) [<xref rid="prp270078-bib-0008" ref-type="bibr">8</xref>, <xref rid="prp270078-bib-0009" ref-type="bibr">9</xref>]. Similarly, the orexinergic system includes orexins A and B (<ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1697" ext-link-type="uri">OXA</ext-link> and <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=1699" ext-link-type="uri">OXB</ext-link>), hypothalamic neuropeptides formed following proteolytic processing of the prepro&#x02010;orexin polypeptide [<xref rid="prp270078-bib-0010" ref-type="bibr">10</xref>]. These endogenous ligands activate the orexin receptor type 1 (<ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=321" ext-link-type="uri">OX<sub>1</sub>
</ext-link>) and orexin receptor type 2 (<ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=322" ext-link-type="uri">OX<sub>2</sub>
</ext-link>), a pair of GPCRs [<xref rid="prp270078-bib-0011" ref-type="bibr">11</xref>]. Cannabinoid and orexin receptors both belong to the rhodopsin&#x02010;like (class A) family of GPCRs [<xref rid="prp270078-bib-0012" ref-type="bibr">12</xref>]. However, CB<sub>1</sub> and CB<sub>2</sub> primarily couple to G&#x003b1;<sub>i/o</sub> G proteins, leading to reduced cAMP production via inhibition of adenylate cyclase, while OX<sub>1</sub> and OX<sub>2</sub> primarily couple to G&#x003b1;<sub>q</sub> G proteins, leading to the production of diacylglycerol (DAG) and inositol trisphosphate (IP<sub>3</sub>) via phospholipase C (PLC) activation [<xref rid="prp270078-bib-0013" ref-type="bibr">13</xref>, <xref rid="prp270078-bib-0014" ref-type="bibr">14</xref>, <xref rid="prp270078-bib-0015" ref-type="bibr">15</xref>].</p><p>The endocannabinoid and orexinergic systems are both implicated in the regulation of physiological processes such as appetite, sleep, reward, memory, nociception, inflammation, and energy homeostasis [<xref rid="prp270078-bib-0012" ref-type="bibr">12</xref>, <xref rid="prp270078-bib-0016" ref-type="bibr">16</xref>]. This, coupled with the shared neuroanatomical distribution of CB<sub>1</sub>, OX<sub>1</sub>, and OX<sub>2</sub> in the hypothalamus, mesocorticolimbic system, brainstem, and other regions of the central nervous system (CNS) suggests that crosstalk may exist between the endocannabinoid and orexinergic systems [<xref rid="prp270078-bib-0012" ref-type="bibr">12</xref>, <xref rid="prp270078-bib-0017" ref-type="bibr">17</xref>]. Several studies have explored cellular and molecular interactions between CB<sub>1</sub> and the orexin receptors. In cells expressing both CB<sub>1</sub> and OX<sub>1</sub>, a CB<sub>1</sub>&#x02010;dependent mechanism is responsible for the 100&#x02010;fold increase in potency for OXA in the mitogen&#x02010;activated protein kinase (MAPK) signaling pathway via OX<sub>1</sub> [<xref rid="prp270078-bib-0018" ref-type="bibr">18</xref>]. Furthermore, when CB<sub>1</sub> and OX<sub>1</sub> are co&#x02010;expressed, the potency of OXA or the synthetic cannabinoid <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=733" ext-link-type="uri">WIN55,212&#x02010;2</ext-link> to phosphorylate ERK1/2 is reduced when treated with the CB<sub>1</sub> antagonist/inverse agonist <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=745" ext-link-type="uri">SR141716</ext-link> or the OX<sub>1</sub> antagonist <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9136" ext-link-type="uri">SB674042</ext-link>, respectively [<xref rid="prp270078-bib-0019" ref-type="bibr">19</xref>]. Additionally, OX<sub>1</sub> activation by OXA has been shown to stimulate the synthesis of the endocannabinoid <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=729" ext-link-type="uri">2&#x02010;arachidonoylglycerol</ext-link> (2&#x02010;AG) via the G&#x003b1;<sub>q</sub> G protein&#x02010;mediated PLC&#x003b2;&#x02010;diacylglycerol lipase&#x02010;&#x003b1; (DAGL&#x003b1;) pathway both in&#x000a0;vitro and in&#x000a0;vivo [<xref rid="prp270078-bib-0020" ref-type="bibr">20</xref>, <xref rid="prp270078-bib-0021" ref-type="bibr">21</xref>]. This 2&#x02010;AG can subsequently activate CB<sub>1</sub> in either an autocrine or paracrine manner [<xref rid="prp270078-bib-0017" ref-type="bibr">17</xref>, <xref rid="prp270078-bib-0021" ref-type="bibr">21</xref>, <xref rid="prp270078-bib-0022" ref-type="bibr">22</xref>]. OXA, which has no affinity for CB<sub>1</sub>, can also promote the internalization of CB<sub>1</sub> but only when co&#x02010;expressed with OX<sub>1</sub>. Furthermore, OXA exhibits greater potency in promoting the internalization of CB<sub>1</sub>&#x02010;OX<sub>1</sub> heterodimers over OX<sub>1</sub> homomers [<xref rid="prp270078-bib-0023" ref-type="bibr">23</xref>]. Far less is known about CB<sub>2</sub>&#x02010;orexin receptor interactions, though CB<sub>2</sub> and OX<sub>1</sub> may form heterotetramers [<xref rid="prp270078-bib-0024" ref-type="bibr">24</xref>].</p><p>In this study, we investigated how orexin receptors can alter cannabinoid receptor&#x02010;mediated signaling in&#x000a0;vitro. Chinese hamster ovary (CHO)&#x02010;K1 cells stably expressing CB<sub>1</sub> or CB<sub>2</sub> were transfected with OX<sub>1</sub> or OX<sub>2</sub> plasmids and evaluated in enzyme fragment complementation (EFC) assays quantifying cyclic adenosine monophosphate (cAMP) inhibition and &#x003b2;arrestin2 recruitment to explore downstream signaling at the cannabinoid receptors. Determining how cannabinoid receptor signaling is influenced by additional GPCRs, such as the orexin receptors, can improve our understanding of the effects of cannabinoid ligands and may uncover novel targets for therapeutic exploitation, especially for physiological processes modulated by both endocannabinoid and orexinergic systems.</p></sec><sec sec-type="materials-and-methods" id="prp270078-sec-0002"><label>2</label><title>Materials and Methods</title><sec id="prp270078-sec-0003"><label>2.1</label><title>Compounds</title><p>
<ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=730" ext-link-type="uri">CP55,940</ext-link> [(&#x02212;)&#x02010;<italic toggle="yes">cis</italic>&#x02010;3&#x02010;[2&#x02010;Hydroxy&#x02010;4&#x02010;(1,1&#x02010;dimethylheptyl)phenyl]&#x02010;<italic toggle="yes">trans</italic>&#x02010;4&#x02010;(3&#x02010;hydroxypropyl)cyclohexanol] was purchased from Tocris Biosciences (Oakville, ON). Forskolin (FSK) was purchased from Sigma&#x02010;Aldrich (Mississauga, ON). CP55,940 and FSK were dissolved in dimethyl sulfoxide (DMSO) with a final concentration of 0.1% DMSO in PBS in assay media for all assays and added directly to media at the concentrations and times indicated.</p></sec><sec id="prp270078-sec-0004"><label>2.2</label><title>Cell Culture</title><p>HitHunter (cAMP) and PathHunter (&#x003b2;arrestin2) CHO&#x02010;K1 cells stably expressing human CB<sub>1</sub> or CB<sub>2</sub> were obtained from DiscoverX (Eurofins, Fremont, CA, USA) and were maintained at 37&#x000b0;C and 5% CO<sub>2</sub> in F&#x02010;12/Dulbecco's Modified Eagle Medium (DMEM) containing 1&#x02009;mM&#x02009;L&#x02010;glutamine, 10% fetal bovine serum (FBS), and 1% penicillin&#x02013;streptomycin (Pen/Strep). Cells were supplemented with 800&#x02009;&#x003bc;g/mL geneticin (HitHunter) or 800&#x02009;&#x003bc;g/mL geneticin and 300&#x02009;&#x003bc;g/mL hygromycin B (PathHunter) [<xref rid="prp270078-bib-0025" ref-type="bibr">25</xref>, <xref rid="prp270078-bib-0026" ref-type="bibr">26</xref>].</p></sec><sec id="prp270078-sec-0005"><label>2.3</label><title>Plasmids</title><p>Human OX<sub>1</sub>&#x02010;enhanced green fluorescent protein (eGFP) and OX<sub>2</sub>&#x02010;eGFP plasmids (henceforth simply described as OX<sub>1</sub> and OX<sub>2</sub>) were sourced from Proxima Research &#x00026; Development (Saskatoon, SK, Canada). All plasmids were propagated and sequenced by Proxima Research &#x00026; Development. For all plasmids, receptor cDNA was inserted into the common pcDNA3.1(+) vector. Receptor plasmids used in transfection experiments are described further in Supporting Information (Figure&#x000a0;<xref rid="prp270078-supitem-0001" ref-type="supplementary-material">S1</xref>).</p></sec><sec id="prp270078-sec-0006"><label>2.4</label><title>Transfections and Microscopy</title><p>Receptor plasmids were introduced into HitHunter CHO&#x02010;K1 cAMP cells and PathHunter CHO&#x02010;K1 &#x003b2;arrestin2 cells using Lipofectamine 3000, according to the manufacturer's instructions (Invitrogen, ThermoFisher Scientific, Waltham, MA, USA). For experiments where cAMP inhibition or &#x003b2;arrestin2 recruitment was measured, cells were grown to ~80% confluency in 10&#x02009;cm tissue culture plates in F&#x02010;12/DMEM containing 1&#x02009;mM&#x02009;L&#x02010;glutamine, 10% FBS, 1% Pen/Strep at 37&#x000b0;C and 5% CO<sub>2</sub>. Cell media was aspirated and cells were washed with 2&#x02009;mL 1X phosphate&#x02010;buffered saline (PBS). Cells were then incubated in serum&#x02010;free media for 30&#x02009;min at 37&#x000b0;C. Lipofectamine 3000 solution was prepared by diluting Lipofectamine 3000 reagent in Opti&#x02010;MEM. Plasmid solution was prepared by diluting plasmid DNA in Opti&#x02010;MEM and P3000 reagent. Diluted Lipofectamine 3000 reagent was then added to the diluted plasmid solution and the resultant solution was incubated for 15&#x02009;min at room temperature. Following this, the Lipofectamine plasmid solution was added to the cells and cells were incubated for 24&#x02013;48&#x02009;h at 37&#x000b0;C and 5% CO<sub>2</sub> prior to conducting experiments. HitHunter CHO&#x02010;K1 cAMP cells and PathHunter CHO&#x02010;K1 &#x003b2;arrestin2 cells were transfected with increasing amounts of OX<sub>1</sub> or OX<sub>2</sub> plasmid (0.10, 0.25, and 0.50&#x02009;&#x003bc;g). CB<sub>1</sub> or CB<sub>2</sub> cells described in figures as receiving 0.00&#x02009;&#x003bc;g OX<sub>1</sub> or 0.00&#x02009;&#x003bc;g OX<sub>2</sub> (i.e., non&#x02010;transfected cells) were used as controls that received a &#x02018;mock' transfection of only the Lipofectamine 3000 and P3000 reagent but without plasmid DNA and were otherwise identical to plasmid transfections. For microscopy experiments, cells were grown to ~50% confluency in 12&#x02010;well tissue culture plates in F&#x02010;12/DMEM containing 1&#x02009;mM&#x02009;L&#x02010;glutamine, 10% FBS, and 1% Pen/Strep at 37&#x000b0;C and 5% CO<sub>2</sub>. Cell media was aspirated and cells were washed with 250&#x02009;&#x003bc;L 1X PBS. Cells were then incubated in serum&#x02010;free media for 30&#x02009;min at 37&#x000b0;C. Lipofectamine 3000 solution was prepared by diluting Lipofectamine 3000 reagent in Opti&#x02010;MEM. Plasmid solution was prepared by diluting plasmid DNA in Opti&#x02010;MEM and P3000 reagent. Diluted Lipofectamine 3000 reagent was then added to the diluted plasmid solution, and the resultant solution was incubated for 15&#x02009;min at room temperature. Following this, the Lipofectamine plasmid solution was added to the cells, and cells were incubated for 48&#x02009;h at 37&#x000b0;C and 5% CO<sub>2</sub> prior to visualization. HitHunter CHO&#x02010;K1 cAMP cells and PathHunter CHO&#x02010;K1 &#x003b2;arrestin2 cells were transfected with 0.50&#x02009;&#x003bc;g of OX<sub>1</sub> or OX<sub>2</sub> plasmid. CB<sub>1</sub> or CB<sub>2</sub> cells described in figures as receiving 0.00&#x02009;&#x003bc;g OX<sub>1</sub> or 0.00&#x02009;&#x003bc;g OX<sub>2</sub> (i.e., non&#x02010;transfected cells) were used as controls that received a &#x02018;mock&#x02019; transfection of only the Lipofectamine 3000 and P3000 reagent but without plasmid DNA and were otherwise identical to plasmid transfections. Hoechst nuclei stain (100&#x02009;mg, ThermoFisher Scientific) was dissolved in 10&#x02009;mL <italic toggle="yes">d</italic>H<sub>2</sub>O to create a 10&#x02009;mg/mL stock solution. The stock Hoechst stain was further diluted 1:5000 in PBS. Forty&#x02010;eight hours after transfection, cell media was removed and replaced with 250&#x02009;&#x003bc;L of diluted Hoechst stain in PBS and incubated for 10&#x02009;min at room temperature protected from light. The staining solution was then removed, and cells were washed three times in 250&#x02009;&#x003bc;L PBS. After removing the last PBS, cells were provided with 200&#x02009;&#x003bc;L FluoroBrite DMEM media (ThermoFisher Scientific). Cells were visualized using a ZOE fluorescent cell imaging system with a 20&#x000d7; objective using brightfield, blue fluorescent, and green fluorescent channels. Brightfield imaging settings were gain 29, exposure 220, LED intensity 26, and contrast 35. Blue (for nuclei) settings were gain 41, exposure 250, LED intensity 7, and contrast 38. Green (for OX receptor eGFP) settings were gain 109, exposure 260, LED intensity 56, and contrast 59. Images were exported as .tif files for subsequent analysis detailed in Section&#x000a0;<xref rid="prp270078-sec-0009" ref-type="sec">2.7</xref>.</p></sec><sec id="prp270078-sec-0007"><label>2.5</label><title>
<styled-content style="fixed-case" toggle="no">HitHunter cAMP</styled-content> Assay</title><p>G&#x003b1;<sub>i/o</sub>&#x02010;mediated inhibition of cAMP production was assessed using the DiscoverX HitHunter assay in CHO&#x02010;K1 CB<sub>1</sub> and CB<sub>2</sub> cAMP cells. CHO&#x02010;K1 cells used in the HitHunter assay stably express unmodified human CB<sub>1</sub> or CB<sub>2</sub> along with an enzyme acceptor (EA) portion of a modified &#x003b2;&#x02010;galactoside enzyme. cAMP levels are quantified through an EFC approach that relies on a modified &#x003b2;&#x02010;galactoside reaction to produce a chemiluminescent signal. In the HitHunter assay, cells are first incubated with ligand&#x02014;in our case the cannabinoid receptor agonist CP55,940&#x02014;that may alter cAMP levels via GPCR&#x02010;dependent signal transduction through G&#x003b1;<sub>i/o</sub> proteins. After this incubation period, cells are treated with a cAMP working solution containing enzyme donor (ED)&#x02010;conjugated cAMP and an anti&#x02010;cAMP antibody solution. The ED&#x02010;conjugated cAMP competes with cellular cAMP for binding to the anti&#x02010;cAMP antibodies. The ED&#x02010;conjugated cAMP is free to complement the EA to form active &#x003b2;&#x02010;galactoside by EFC. Last, a modified &#x003b2;&#x02010;galactoside substrate is added that can be hydrolyzed by the whole enzyme to produce light. In this competition, the antibody&#x02010;bound ED&#x02010;cAMP cannot complement the EA, but unbound ED&#x02010;cAMP can complement EA to form active enzyme, consequently producing luminescence. The amount of signal produced is directly proportional to the amount of cAMP in the cells. In our assays measuring cAMP changes in response to GPCR signaling via a G&#x003b1;<sub>i/o</sub>&#x02010;coupled receptor, cAMP levels (and therefore chemiluminescence) decline. From a technical standpoint, the assay proceeded as follows: cells were dissociated from 10&#x02009;cm tissue culture plates using 2&#x02009;mL 0.5% trypsin&#x02013;EDTA and replated into white&#x02010;walled, white&#x02010;bottom, flat&#x02010;bottom 96&#x02010;well tissue culture plates at a density of 20,000 cells/well. Plates were incubated overnight in Opti&#x02010;MEM containing 1% FBS at 37&#x000b0;C and 5% CO<sub>2</sub>. The next day, Opti&#x02010;MEM media was removed and replaced with cell assay buffer (1X PBS). Subsequently, cells were left untreated or treated with 0.1% DMSO in PBS containing 10&#x02009;&#x003bc;M FSK and 0.1&#x02009;nM to 10&#x02009;&#x003bc;M ligands for 90&#x02009;min at 37&#x000b0;C. cAMP antibody solution and ED&#x02010;conjugated cAMP solution were then added to cells according to the manufacturer's directions (DiscoverX). Cells were incubated with these solutions for 60&#x02009;min at room temperature protected from light. &#x003b2;&#x02010;galactoside substrate (i.e., cAMP solution A) was added according to the manufacturer's directions (DiscoverX) and cells were incubated for an additional 3&#x02009;h at room temperature protected from light. Chemiluminescence was measured on a BioTek Synergy HT microplate reader (BioTek Instruments, Winooski, VT) with the following settings: top read, gain 200, integration time 1000&#x02009;ms [<xref rid="prp270078-bib-0025" ref-type="bibr">25</xref>, <xref rid="prp270078-bib-0026" ref-type="bibr">26</xref>]. Raw data for the untreated and vehicle with FSK&#x02010;treated controls is presented in Figure&#x000a0;<xref rid="prp270078-supitem-0001" ref-type="supplementary-material">S2</xref>.</p></sec><sec id="prp270078-sec-0008"><label>2.6</label><title>
<styled-content style="fixed-case" toggle="no">PathHunter</styled-content> &#x003b2;arrestin2 Assay</title><p>&#x003b2;arrestin2 recruitment was assessed using the DiscoverX PathHunter assay in CHO&#x02010;K1 CB<sub>1</sub> and CB<sub>2</sub> &#x003b2;arrestin2 cells. CHO&#x02010;K1 cells used in the PathHunter assay stably express human CB<sub>1</sub> or CB<sub>2</sub> conjugated to the ED portion of a modified &#x003b2;&#x02010;galactoside enzyme and &#x003b2;arrestin2 conjugated to the EA portion of a modified &#x003b2;&#x02010;galactoside enzyme. Recruitment of &#x003b2;arrestin2 to a GPCR is quantified through an EFC approach that relies on a modified &#x003b2;&#x02010;galactoside reaction to produce a chemiluminescent signal. In the PathHunter assay, cells are first incubated with ligand&#x02014;in our case the cannabinoid receptor agonist CP55,940&#x02014;that may result in the recruitment of &#x003b2;arrestin2 to the GPCR. After this incubation period, cells are treated with a modified &#x003b2;&#x02010;galactoside substrate that can be hydrolyzed by the whole enzyme to produce light. The amount of signal produced is directly proportional to the amount of &#x003b2;arrestin2 recruitment occurring in the cells. From a technical standpoint, the assay proceeded as follows: cells were dissociated from 10&#x02009;cm tissue culture plates using 2&#x02009;mL 0.5% trypsin&#x02013;EDTA and replated into white&#x02010;walled, white&#x02010;bottom, flat&#x02010;bottom 96&#x02010;well tissue culture plates at a density of 20,000 cells/well. Plates were incubated overnight in Opti&#x02010;MEM containing 1% FBS at 37&#x000b0;C and 5% CO<sub>2</sub>. Afterwards, cells were left untreated or treated with 0.1% DMSO in PBS or 0.1&#x02009;nM&#x02013;10&#x02009;&#x003bc;M ligands for 90&#x02009;min at 37&#x000b0;C. Detection solution (i.e., &#x003b2;&#x02010;galactoside substrate) was then added to cells according to the manufacturer's directions (DiscoverX) and cells were incubated for 60&#x02009;min at room temperature. Chemiluminescence was measured on a BioTek Synergy HT microplate reader (BioTek Instruments, Winooski, VT) with the following settings: top read, gain 200, integration time 1000&#x02009;ms [<xref rid="prp270078-bib-0025" ref-type="bibr">25</xref>, <xref rid="prp270078-bib-0026" ref-type="bibr">26</xref>].</p></sec><sec id="prp270078-sec-0009"><label>2.7</label><title>Image Analysis</title><p>Image files were imported into Fiji ImageJ v. 1.54i [<xref rid="prp270078-bib-0027" ref-type="bibr">27</xref>] to count the number of OX<sub>1</sub> or OX<sub>2</sub>&#x02010;expressing cells based on their green fluorescence as a percentage of the number of Hoechst&#x02010;stained cells. Imported .tif images were first duplicated and the duplicates converted from RGB to 8&#x02010;bit format; then, an image threshold adjustment was applied using the &#x0201c;Threshold&#x0201d; tool with default settings. Images were then processed into Binary images and converted to a Mask, again using default settings. The &#x0201c;Watershed&#x0201d; tool was then applied to separate clusters of cells that would otherwise be counted as single objects. Cells were then counted using the &#x0201c;Analyze Particles&#x0201d; tool with the particle size set to 10&#x02014;infinity pixels<sup>2</sup> and all other settings kept as default. The percentage of receptor&#x02010;expressing cells was then estimated by dividing the number of green cells in a given field of view by the number of Hoechst&#x02010;stained nuclei in that same field of view, multiplied by 100.</p></sec><sec id="prp270078-sec-0010"><label>2.8</label><title>Statistical Analyses</title><p>Statistical analyses were conducted using GraphPad Prism 9.0 (GraphPad Software Inc., San Diego, CA, USA). All assays were conducted with a minimum <italic toggle="yes">n</italic>&#x02009;=&#x02009;4 independent experiments as indicated in figure legends with 3 technical replicates per treatment per experiment. In the whole of the study, 3 technical replicate datapoints from a single experiment were excluded because the experimenter noted technical issues in the execution of that experiment. Data for cAMP inhibition and &#x003b2;arrestin2 recruitment in untreated cells and cells receiving 0.1% DMSO +10&#x02009;&#x003bc;M FSK in PBS (cAMP) or 0.1% DMSO in PBS (&#x003b2;arrestin2) are represented as fold compared to non&#x02010;transfected untreated cells (i.e., 1; Figures&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2A,C</xref>, <xref rid="prp270078-fig-0003" ref-type="fig">3A,C</xref>, <xref rid="prp270078-fig-0004" ref-type="fig">4A,C,</xref> and <xref rid="prp270078-fig-0005" ref-type="fig">5A,C</xref>) For clarity this meant that in cAMP experiments the vehicle treatment contained 0.1% DMSO +10&#x02009;&#x003bc;M FSK in PBS; and for &#x003b2;arrestin2 experiments the vehicle contained 0.1% DMSO in PBS. For all concentration&#x02010;response curves (CRC; Figures&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2B,D</xref>, <xref rid="prp270078-fig-0003" ref-type="fig">3B,D</xref>, <xref rid="prp270078-fig-0004" ref-type="fig">4B,D,</xref> and <xref rid="prp270078-fig-0005" ref-type="fig">5B,D</xref>), raw data were transformed in GraphPad Prism using the formula &#x0201c;Y&#x02009;=&#x02009;Y/K&#x0201d; where &#x02018;K' represented the mean <italic toggle="yes">E</italic>
<sub>min</sub> observed for the CRC obtained from raw data in a single 96&#x02010;well plate for that treatment group. In considering our data, several analytical approaches were considered; however, because the level of receptor expression was not measured within the cells used for experiments we did not think it appropriate to normalize to a set compound&#x02010;based parameter such as % FSK response. Therefore, we provide the data for cellular responses to no treatment and the solutions of 0.1% DMSO +10&#x02009;&#x003bc;M FSK in PBS (cAMP) or 0.1% DMSO in PBS (&#x003b2;arrestin2) alongside the concentration&#x02010;response data. CRCs were fit using variable slope non&#x02010;linear regression (i.e., 4&#x02010;parameters) or the Hill slope was constrained to 1, where specifically noted. CRCs were used to estimate pEC<sub>50</sub> and <italic toggle="yes">E</italic>
<sub>max</sub> values. Statistical analyses were conducted by one&#x02010;way analysis of variance (ANOVA) or two&#x02010;way ANOVA, as indicated in the figure and table descriptions. <italic toggle="yes">Post hoc</italic> analyses were performed using Tukey's test. All values are expressed as the mean&#x02009;&#x000b1;&#x02009;the standard error of the mean (SEM) or 95% confidence interval (CI), as indicated. <italic toggle="yes">p</italic> values &#x0003c;&#x02009;0.05 were considered significant.</p></sec><sec id="prp270078-sec-0011"><label>2.9</label><title>Nomenclature of Targets and Ligands</title><p>Key protein targets and ligands in this article are hyperlinked to corresponding entries in <ext-link xlink:href="http://www.guidetopharmacology.org" ext-link-type="uri">http://www.guidetopharmacology.org</ext-link>, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [<xref rid="prp270078-bib-0028" ref-type="bibr">28</xref>], and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 [<xref rid="prp270078-bib-0029" ref-type="bibr">29</xref>].</p></sec></sec><sec sec-type="results" id="prp270078-sec-0012"><label>3</label><title>Results</title><sec id="prp270078-sec-0013"><label>3.1</label><title>Estimation of Transfection Efficiency</title><p>Because our experimental approach utilized CHO&#x02010;K1 cells stably expressing cannabinoid receptors but transiently transfected with orexin receptors, the transfection efficiency of Lipofectamine 3000 was estimated by counting the number of eGFP&#x02010;expressing cells relative to the number of Hoechst&#x02010;stained nuclei in a given field of view 48&#x02009;h after transfection. The lowest transfection efficiency was observed in CHO&#x02010;K1 cAMP CB<sub>1</sub> cells transfected with OX<sub>1</sub> (19%) and the highest transfection efficiency was observed in CHO&#x02010;K1 cAMP CB<sub>2</sub> cells transfected with OX<sub>2</sub> (75%) (Figure&#x000a0;<xref rid="prp270078-fig-0001" ref-type="fig">1A</xref>). However, transfection efficiency was not different between CB<sub>1</sub>&#x02010;expressing cells and CB<sub>2</sub>&#x02010;expressing cells. A subset of CHO&#x02010;K1 cAMP cells was also treated only with Lipofectamine 3000 for this experiment (i.e., &#x02018;Mock&#x02019; transfected) and some green background fluorescence was observed in these cells using the same microscope and ImageJ analysis settings, such that the percentage of eGFP&#x02010;positive cells in these experiments was 3.5% and 2.6% for CB<sub>1</sub> and CB<sub>2</sub>, respectively (Figure&#x000a0;<xref rid="prp270078-fig-0001" ref-type="fig">1A</xref>). Representative micrographs are displayed in Figure&#x000a0;<xref rid="prp270078-fig-0001" ref-type="fig">1B</xref>, and a full catalogue of all images is displayed in Supporting Information (Figure&#x000a0;<xref rid="prp270078-supitem-0001" ref-type="supplementary-material">S3</xref>).</p><fig position="float" fig-type="FIGURE" id="prp270078-fig-0001"><label>FIGURE 1</label><caption><p>Estimation of transfection efficiency. CHO cells stably expressing CB<sub>1</sub> and transiently transfected with either OX<sub>1</sub> or OX<sub>2</sub>&#x02010;eGFP plasmids were stained with Hoechst to visualize nuclei and observed to estimate transfection efficiency based on the number of cells expressing eGFP (A). Data are mean&#x02009;&#x000b1;&#x02009;SEM from <italic toggle="yes">n</italic>&#x02009;=&#x02009;3 (Mock) or 9 independent experiments. (B) Representative images for data presented in panel (A). Scale bar represents 100&#x02009;&#x003bc;m.</p></caption><graphic xlink:href="PRP2-13-e70078-g003" position="anchor" id="jats-graphic-3"/></fig></sec><sec id="prp270078-sec-0014"><label>3.2</label><title>Modulation of <styled-content style="fixed-case" toggle="no">cAMP</styled-content> and &#x003b2;arrestin2 Recruitment in <styled-content style="fixed-case" toggle="no">CB<sub>1</sub>
</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">OX<sub>1</sub>
</styled-content> Transfected Cells</title><p>In untreated cells, increasing the amount of OX<sub>1</sub> did not significantly change the cAMP response (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2A</xref>). Cells treated with the compound solvent, which included 0.1% DMSO and 10&#x02009;&#x003bc;M FSK, saw statistically significantly higher levels of cAMP as expected following FSK treatment; and this effect was greater in cells transfected with 0.10 and 0.25&#x02009;&#x003bc;g OX<sub>1</sub> compared to non&#x02010;transfected cells or cells transfected with 0.50&#x02009;&#x003bc;g OX<sub>1</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2A</xref>). Transfected and non&#x02010;transfected cells were treated with increasing concentrations of CP55,940 (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2B</xref>). These data were first transformed relative to the <italic toggle="yes">E</italic>
<sub>min</sub> for each CRC as described in the Methods. Doing so constrained the CRC <italic toggle="yes">E</italic>
<sub>min</sub> to 1 so that curves for different amounts of transfected plasmid that had variable fold responses in Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2A</xref> were made comparable in Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2B</xref>. By constraining the <italic toggle="yes">E</italic>
<sub>min</sub> to 1 in this way, differences in potency and efficacy as a function of CP55,940 were compared under each transfection condition that were not overestimated through the inclusion of different basal vehicle conditions. In cells that were not transfected with OX<sub>1</sub>, a concentration&#x02010;response for CP55,940 was observed with a potency of 1.5&#x02009;nM (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2B</xref>); however, the goodness of fit was relatively low (<italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.25) albeit with reasonable residual standard deviation (Sy.x&#x02009;=&#x02009;0.16) and so conclusions about shifts in potency should be interpreted with caution. Among transfected cells, as the amount of OX<sub>1</sub> increased, CP55,940's potency decreased; however, this shift was not statistically significant (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2B</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0001" ref-type="table">1</xref>). E<sub>max</sub> was greater in cells transfected with 0.10 or 0.25&#x02009;&#x003bc;g OX<sub>1</sub>, but cells transfected with 0.50&#x02009;&#x003bc;g OX<sub>1</sub> did not display greater efficacy compared to cells without OX<sub>1</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2B</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0001" ref-type="table">1</xref>). In addition, transfection with 0.50&#x02009;&#x003bc;g OX<sub>1</sub> resulted in a CRC that could not be fit to a 4&#x02010;parameter model (Table&#x000a0;<xref rid="prp270078-tbl-0001" ref-type="table">1</xref>). This may indicate that at plasmid levels above 0.25&#x02009;&#x003bc;g OX<sub>1</sub>, there may have been signaling interference as a result of OX<sub>1</sub> coupling to G&#x003b1;<sub>i/o</sub> or G&#x003b1;<sub>S</sub> because coupling to these G proteins has been detected reviewed in [<xref rid="prp270078-bib-0030" ref-type="bibr">30</xref>]. Alternatively, OX<sub>1</sub>&#x02010;mediated signaling via G&#x003b1;<sub>q</sub> interfered with G&#x003b1;<sub>i/o</sub> signaling [<xref rid="prp270078-bib-0030" ref-type="bibr">30</xref>]. Overall, these data suggest that the presence of OX<sub>1</sub> enhanced CB<sub>1</sub>&#x02010;dependent cAMP inhibition. In untreated cells, 0.10&#x02009;&#x003bc;g OX<sub>1</sub> reduced CB<sub>1</sub>&#x02010;dependent &#x003b2;arrestin2 recruitment; whereas 0.25&#x02009;&#x003bc;g OX<sub>1</sub> was not different from cells without OX<sub>1</sub>, and 0.50&#x02009;&#x003bc;g OX<sub>1</sub> produced greater &#x003b2;arrestin2 recruitment than 0.00, 0.10, or 0.25&#x02009;&#x003bc;g OX<sub>1</sub> in untreated cells (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2C</xref>). Similarly, in cells that received 0.1% DMSO in PBS, &#x003b2;arrestin2 recruitment was greater in cells transfected with 0.50&#x02009;&#x003bc;g OX<sub>1</sub> compared to cells transfected with 0.00, 0.10, or 0.25&#x02009;&#x003bc;g OX<sub>1</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2C</xref>). An effect of vehicle (0.1% DMSO in PBS) compared to untreated was present for cells transfected with 0.50&#x02009;&#x003bc;g OX<sub>1</sub>; it is not clear whether this effect was biologically significant, but it is reported to show the vehicle did affect our observations under some conditions (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2C</xref>). As with Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2A,B</xref>, CRC data in Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2D</xref> were constrained to an <italic toggle="yes">E</italic>
<sub>min</sub> of 1 to allow for comparisons of potency and efficacy following CP55,940 treatment. The CRC for CP55,940 in CHO&#x02010;K1 CB<sub>1</sub> &#x003b2;arrestin2 cells that were not transfected did not reach a clear asymptote, and so the reported <italic toggle="yes">E</italic>
<sub>max</sub> is based on the observed result rather than the nonlinear regression (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2D</xref>). In comparison, the potency of CP55,940 among transfected cells appeared to increase as the amount of OX<sub>1</sub> increased, although this trend was not statistically significant (Table&#x000a0;<xref rid="prp270078-tbl-0001" ref-type="table">1</xref>). The presence of OX<sub>1</sub> reduced CP55,940's efficacy in the &#x003b2;arrestin2 recruitment assay, although this was not statistically significant (Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2D</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0001" ref-type="table">1</xref>). These data suggest that the effect of OX<sub>1</sub> on CB<sub>1</sub>&#x02010;dependent &#x003b2;arrestin2 recruitment may depend on the specific treatment the cells are exposed to: &#x003b2;arrestin2 recruitment increased as a function of transfecting higher amounts of OX<sub>1</sub> into cells while CP55,940&#x02010;treated cells exhibited reduced &#x003b2;arrestin2 recruitment.</p><fig position="float" fig-type="FIGURE" id="prp270078-fig-0002"><label>FIGURE 2</label><caption><p>CB<sub>1</sub>&#x02010;dependent inhibition of cAMP and &#x003b2;arrestin2 recruitment in CB<sub>1</sub>&#x02010;OX<sub>1</sub> cells. CHO cells stably expressing CB<sub>1</sub> and transiently expressing OX<sub>1</sub> were treated with 10&#x02009;&#x003bc;M FSK and 0.1&#x02009;nM&#x02014;10&#x02009;&#x003bc;M CP55,940 for 90&#x02009;min to measure cAMP inhibition (A, B) or 0.1&#x02009;nM&#x02014;10&#x02009;&#x003bc;M CP55,940 for 90&#x02009;min to measure &#x003b2;arrestin2 recruitment (C, D). Data were fit to a 4&#x02010;parameter non&#x02010;linear regression and are represented as fold over vehicle. Data are mean&#x02009;&#x000b1;&#x02009;SEM from <italic toggle="yes">n</italic>&#x02009;=&#x02009;4&#x02013;8 independent experiments performed in triplicate. *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, ****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 within treatment between groups; <sup>#</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, <sup>####</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 within groups between treatments as determined by two&#x02010;way ANOVA followed by Tukey's post hoc test.</p></caption><graphic xlink:href="PRP2-13-e70078-g006" position="anchor" id="jats-graphic-5"/></fig><table-wrap position="float" id="prp270078-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>CB<sub>1</sub>&#x02010;dependent inhibition of cAMP and recruitment of &#x003b2;arrestin2 in CB<sub>1</sub>&#x02010;OX<sub>1</sub> cells.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">[OX<sub>1</sub>] (&#x003bc;g)</th><th align="center" colspan="3" valign="bottom" rowspan="1">cAMP</th><th align="center" colspan="3" valign="bottom" rowspan="1">&#x003b2;arrestin2</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">pEC<sub>50</sub> (nM)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max</sub> (Fold)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hill slope</th><th align="center" valign="bottom" rowspan="1" colspan="1">pEC<sub>50</sub> (nM)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max</sub> (Fold)<xref rid="prp270078-note-0007" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hill slope</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="center" valign="top" rowspan="1" colspan="1">8.8&#x02009;&#x000b1;&#x02009;0.45 (1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.79&#x02009;&#x000b1;&#x02009;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.7&#x02009;&#x000b1;&#x02009;3.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;5 (&#x0003e;&#x02009;10&#x02009;000)</td><td align="center" valign="top" rowspan="1" colspan="1">17&#x02009;&#x000b1;&#x02009;4.6</td><td align="center" valign="top" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">8.1&#x02009;&#x000b1;&#x02009;0.24 (7.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.57&#x02009;&#x000b1;&#x02009;0.03<xref rid="prp270078-note-0004" ref-type="table-fn">**</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.2&#x02009;&#x000b1;&#x02009;0.90</td><td align="center" valign="top" rowspan="1" colspan="1">5.5&#x02009;&#x000b1;&#x02009;1.4 (3000)</td><td align="center" valign="top" rowspan="1" colspan="1">5.7&#x02009;&#x000b1;&#x02009;3.2</td><td align="center" valign="top" rowspan="1" colspan="1">0.41&#x02009;&#x000b1;&#x02009;0.23</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">7.9&#x02009;&#x000b1;&#x02009;0.16 (12)</td><td align="center" valign="top" rowspan="1" colspan="1">0.52&#x02009;&#x000b1;&#x02009;0.03<xref rid="prp270078-note-0005" ref-type="table-fn">***</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.77&#x02009;&#x000b1;&#x02009;0.22</td><td align="center" valign="top" rowspan="1" colspan="1">6.0&#x02009;&#x000b1;&#x02009;0.26 (960)</td><td align="center" valign="top" rowspan="1" colspan="1">5.6&#x02009;&#x000b1;&#x02009;0.63</td><td align="center" valign="top" rowspan="1" colspan="1">0.46&#x02009;&#x000b1;&#x02009;0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="center" valign="top" rowspan="1" colspan="1">7.9&#x02009;&#x000b1;&#x02009;0.33 (11)<xref rid="prp270078-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.69&#x02009;&#x000b1;&#x02009;0.03<xref rid="prp270078-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1<xref rid="prp270078-note-0006" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;0.068 (400)</td><td align="center" valign="top" rowspan="1" colspan="1">6.4&#x02009;&#x000b1;&#x02009;0.21</td><td align="center" valign="top" rowspan="1" colspan="1">0.70&#x02009;&#x000b1;&#x02009;0.06</td></tr></tbody></table><table-wrap-foot id="prp270078-ntgp-0002"><fn id="prp270078-note-0002"><p>
<italic toggle="yes">Note:</italic> Data were fit to a 4&#x02010;parameter non&#x02010;linear regression to estimate potency (pEC<sub>50</sub>) and efficacy (<italic toggle="yes">E</italic>
<sub>max</sub>) values. Data are expressed as mean&#x02009;&#x000b1;&#x02009;SEM. <italic toggle="yes">n</italic>&#x02009;=&#x02009;4&#x02013;8 independent experiments performed in triplicate. Statistical analyses were by one&#x02010;way ANOVA followed by Tukey's post hoc test. Data presented in the Table relate to Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2</xref>.</p></fn><fn id="prp270078-note-0003"><p>Abbreviation: n.d., not determined.</p></fn><fn id="prp270078-note-0004"><label>**</label><p>
<italic toggle="yes">p</italic> &#x0003c; 0.01 relative to CP55,940.</p></fn><fn id="prp270078-note-0005"><label>***</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 relative to CP55,940.</p></fn><fn id="prp270078-note-0006"><label>
<sup>a</sup>
</label><p>When fit to a 4&#x02010;parameter model, pEC<sub>50</sub> and Hill Slope could not be accurately estimated, data in table are for a Hill Slope constrained to 1.</p></fn><fn id="prp270078-note-0007"><label>
<sup>b</sup>
</label><p>
<italic toggle="yes">E</italic>
<sub>max</sub> data represent the experimentally observed value because CRC did not reach a clearly defined maximum asymptote; for this reason EC<sub>50</sub> is reported as&#x02009;&#x0003e;&#x02009;10&#x02009;000&#x02009;nM.</p></fn></table-wrap-foot></table-wrap></sec><sec id="prp270078-sec-0015"><label>3.3</label><title>Modulation of <styled-content style="fixed-case" toggle="no">cAMP</styled-content> and &#x003b2;arrestin2 Recruitment in <styled-content style="fixed-case" toggle="no">CB<sub>1</sub>
</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">OX<sub>2</sub>
</styled-content> Transfected Cells</title><p>In untreated cells, no significant difference was observed in the cAMP response as the amount of OX<sub>2</sub> increased (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3A</xref>). In cells receiving 0.1% DMSO in PBS with 10&#x02009;&#x003bc;M FSK, there was a trend toward increased cAMP levels with FSK, but these differences were not significant; similar to untreated cells, OX<sub>2</sub> transfection did not yield a significant difference in cAMP response (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3A</xref>). Data for CB<sub>1</sub>&#x02010;expressing cells that were not transfected with OX<sub>1</sub> are identical in Figures&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2B</xref> and <xref rid="prp270078-fig-0003" ref-type="fig">3B</xref>; therefore, because the goodness of fit was relatively low (<italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.25) albeit with reasonable residual standard deviation (Sy.x&#x02009;=&#x02009;0.16) conclusions about shifts in potency should be interpreted with caution. As in Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2</xref>, CRC data in Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3B,D</xref> were constrained such that <italic toggle="yes">E</italic>
<sub>min</sub>&#x02009;=&#x02009;1 to allow for comparisons of potency and efficacy following CP55,940 treatment. Among transfected cells, the presence of OX<sub>2</sub> enhanced both the potency and efficacy of CP55,940, although the shift in potency was not assessed by ANOVA because the estimated potency was outside the range of CP55,940 used in the assay (i.e., &#x0003c;&#x02009;0.1&#x02009;nM) (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3B</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0002" ref-type="table">2</xref>). These data suggest that OX<sub>2</sub> enhanced CP55,940&#x02010;mediated cAMP inhibition via CB<sub>1</sub>. In untreated cells and cells that received 0.1% DMSO in PBS, transfection with 0.25 or 0.50&#x02009;&#x003bc;g OX<sub>2</sub> reduced &#x003b2;arrestin2 recruitment compared to cells without OX<sub>2</sub> and when 0.10&#x02009;&#x003bc;g OX<sub>2</sub> was compared to 0.25&#x02009;&#x003bc;g OX<sub>2</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3C</xref>). Cells that received 0.1% DMSO in PBS that were transfected with 0.25&#x02009;&#x003bc;g OX<sub>2</sub> displayed less &#x003b2;arrestin2 recruitment than cells transfected with 0.00, 0.10, or 0.50&#x02009;&#x003bc;g OX<sub>2</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3C</xref>). Treatment with 0.1% DMSO in PBS also appears to have reduced &#x003b2;arrestin2 recruitment compared to untreated cells that received 0.00 or 0.10&#x02009;&#x003bc;g OX<sub>2</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3C</xref>); as in Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2C</xref>. it is unknown whether this is biologically significant but is reported to show the vehicle did affect our observations under some conditions. The CRC for CP55,940 in CHO&#x02010;K1 CB<sub>1</sub> &#x003b2;arrestin2 cells that were not transfected (same as in Figure&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2D</xref>) did not reach a clear asymptote, and so the reported <italic toggle="yes">E</italic>
<sub>max</sub> is based on the observed result rather than the nonlinear regression (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3D</xref>). Accordingly, the potency of CP55,940 in these experiments could not be accurately estimated (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3D</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0002" ref-type="table">2</xref>). A statistically significant increase in the observed maximum response of CP55,940 was observed for all transfection groups (Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3D</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0002" ref-type="table">2</xref>). These data suggest that the presence of OX<sub>2</sub> can reduce CB<sub>1</sub>&#x02010;mediated &#x003b2;arrestin2 recruitment in the absence of an agonist or facilitate CB<sub>1</sub>&#x02010;mediated &#x003b2;arrestin2 recruitment in the presence of an agonist. &#x003b2;arrestin2 recruitment was reduced as a function of increasing OX<sub>2</sub> amounts, whereas CP55,940 treatment increased &#x003b2;arrestin2 recruitment as a function of increasing OX<sub>2</sub> amounts.</p><fig position="float" fig-type="FIGURE" id="prp270078-fig-0003"><label>FIGURE 3</label><caption><p>CB<sub>1</sub>&#x02010;dependent inhibition of cAMP and &#x003b2;arrestin2 recruitment in CB<sub>1</sub>&#x02010;OX<sub>2</sub> cells. CHO cells stably expressing CB<sub>1</sub> and transiently expressing OX<sub>2</sub> were treated with 10&#x02009;&#x003bc;M FSK and 0.1&#x02009;nM&#x02013;10&#x02009;&#x003bc;M CP55,940 for 90&#x02009;min to measure cAMP inhibition (A, B) or 0.1&#x02009;nM&#x02013;10&#x02009;&#x003bc;M CP55,940 for 90&#x02009;min to measure &#x003b2;arrestin2 recruitment (C, D). Data were fit to a 4&#x02010;parameter non&#x02010;linear regression and are represented as fold over vehicle. Data are mean&#x02009;&#x000b1;&#x02009;SEM from <italic toggle="yes">n</italic>&#x02009;=&#x02009;4&#x02013;8 independent experiments performed in triplicate. *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 within treatment between groups; <sup>##</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>####</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 within groups between treatments as determined by two&#x02010;way ANOVA followed by Tukey's post hoc test.</p></caption><graphic xlink:href="PRP2-13-e70078-g005" position="anchor" id="jats-graphic-7"/></fig><table-wrap position="float" id="prp270078-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>CB<sub>1</sub>&#x02010;dependent inhibition of cAMP and recruitment of &#x003b2;arrestin2 in CB<sub>1</sub>&#x02010;OX<sub>2</sub> cells.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">[OX<sub>2</sub>] (&#x003bc;g)</th><th align="center" colspan="3" valign="bottom" rowspan="1">cAMP</th><th align="center" colspan="3" valign="bottom" rowspan="1">&#x003b2;arrestin2</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">pEC<sub>50</sub> (nM)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max</sub> (Fold)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hill slope</th><th align="center" valign="bottom" rowspan="1" colspan="1">pEC<sub>50</sub> (nM)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max</sub> (Fold)<xref rid="prp270078-note-0013" ref-type="table-fn">
<sup>a</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hill slope</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="center" valign="top" rowspan="1" colspan="1">8.8&#x02009;&#x000b1;&#x02009;0.45 (1.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.79&#x02009;&#x000b1;&#x02009;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.7&#x02009;&#x000b1;&#x02009;3.6</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;5 (&#x0003e;&#x02009;10&#x02009;000)</td><td align="center" valign="top" rowspan="1" colspan="1">17&#x02009;&#x000b1;&#x02009;4.6</td><td align="center" valign="top" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">9.4&#x02009;&#x000b1;&#x02009;2.5 (1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.62&#x02009;&#x000b1;&#x02009;0.07</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.5&#x02009;&#x000b1;&#x02009;0.66</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;5 (&#x0003e;&#x02009;10&#x02009;000)</td><td align="center" valign="top" rowspan="1" colspan="1">33&#x02009;&#x000b1;&#x02009;0.92<xref rid="prp270078-note-0010" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;&#x02009;10 (&#x0003c;&#x02009;0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.58&#x02009;&#x000b1;&#x02009;0.06<xref rid="prp270078-note-0010" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.39&#x02009;&#x000b1;&#x02009;0.59</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;5 (&#x0003e;&#x02009;10&#x02009;000)</td><td align="center" valign="top" rowspan="1" colspan="1">41&#x02009;&#x000b1;&#x02009;1.5<xref rid="prp270078-note-0011" ref-type="table-fn">**</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003e;&#x02009;10 (&#x0003c;&#x02009;0.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.43&#x02009;&#x000b1;&#x02009;0.06<xref rid="prp270078-note-0012" ref-type="table-fn">***</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;0.35&#x02009;&#x000b1;&#x02009;0.45</td><td align="center" valign="top" rowspan="1" colspan="1">&#x0003c;&#x02009;5 (&#x0003e;&#x02009;10&#x02009;000)</td><td align="center" valign="top" rowspan="1" colspan="1">39&#x02009;&#x000b1;&#x02009;3.8<xref rid="prp270078-note-0011" ref-type="table-fn">**</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">n.d.</td></tr></tbody></table><table-wrap-foot id="prp270078-ntgp-0003"><fn id="prp270078-note-0008"><p>
<italic toggle="yes">Note:</italic> Data were fit to a 4&#x02010;parameter non&#x02010;linear regression to estimate potency (pEC<sub>50</sub>) and efficacy (<italic toggle="yes">E</italic>
<sub>max</sub>) values. Data are expressed as mean&#x02009;&#x000b1;&#x02009;SEM. <italic toggle="yes">n</italic>&#x02009;=&#x02009;4&#x02013;8 independent experiments performed in triplicate. If potency could not be estimated (i.e., &#x0003c;&#x02009;0.1&#x02009;nM or &#x0003e;&#x02009;10&#x02009;000&#x02009;nM), then <italic toggle="yes">E</italic>
<sub>max</sub> is reported as the mean of the greatest response observed. Statistical analyses were by one&#x02010;way ANOVA followed by Tukey's post hoc test. Data presented in the Table relate to Figure&#x000a0;<xref rid="prp270078-fig-0003" ref-type="fig">3</xref>.</p></fn><fn id="prp270078-note-0009"><p>Abbreviation: n.d., not determined.</p></fn><fn id="prp270078-note-0010"><label>*</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn><fn id="prp270078-note-0011"><label>**</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></fn><fn id="prp270078-note-0012"><label>***</label><p>
<italic toggle="yes">p</italic> &#x0003c; 0.001 relative to CP55,940.</p></fn><fn id="prp270078-note-0013"><label>
<sup>a</sup>
</label><p>
<italic toggle="yes">E</italic>
<sub>max</sub> data represent the experimentally observed value because CRC did not reach a clearly defined maximum asymptote; for this reason EC<sub>50</sub> is reported as&#x02009;&#x0003e;&#x02009;10&#x02009;000&#x02009;nM.</p></fn></table-wrap-foot></table-wrap></sec><sec id="prp270078-sec-0016"><label>3.4</label><title>Modulation of <styled-content style="fixed-case" toggle="no">cAMP</styled-content> and &#x003b2;arrestin2 Recruitment in <styled-content style="fixed-case" toggle="no">CB<sub>2</sub>
</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">OX<sub>1</sub>
</styled-content> Transfected Cells</title><p>No statistical difference in cAMP levels was detected between untreated cells receiving varying amounts of OX<sub>1</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4A</xref>). Ten micrometer FSK in 0.1% DMSO with PBS increased the cAMP response as expected compared to untreated cells, and this difference was statistically significant in cells receiving 0.25 and 0.50&#x02009;&#x003bc;g OX<sub>1</sub> compared to untreated cells (Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4A</xref>). Cells transfected with 0.10&#x02009;&#x003bc;g OX<sub>1</sub> that received 10&#x02009;&#x003bc;M FSK in 0.1% DMSO and PBS saw a cAMP response that was lower compared to cells transfected with 0.50&#x02009;&#x003bc;g OX<sub>1</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4A</xref>). As above, CRC data in Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4B,D</xref> were constrained for <italic toggle="yes">E</italic>
<sub>min</sub>&#x02009;=&#x02009;1 to allow for comparisons of potency and efficacy following CP55,940 treatment. In cells that were not transfected with OX<sub>2</sub>, a concentration&#x02010;response for CP55,940 was observed with a potency of 10&#x02009;nM if the Hill Slope was constrained to 1 (Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4B</xref>); however, the goodness of fit was relatively low (<italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.21) albeit with reasonable residual standard deviation (Sy.x&#x02009;=&#x02009;0.092); therefore, these data should be interpreted with caution. Potency could not be determined for cells transfected with 0.10, 0.25, or 0.50&#x02009;&#x003bc;g OX<sub>1</sub>, as no concentration&#x02010;response was clearly observed (Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4B</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0003" ref-type="table">3</xref>). The efficacy of CP55,940 decreased as the amount of OX<sub>1</sub> increased, though this was only statistically significant for cells transfected with 0.10&#x02009;&#x003bc;g OX<sub>1</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4B</xref>). These data suggest that OX<sub>1</sub> prevents CB<sub>2</sub>&#x02010;dependent cAMP inhibition. Basal &#x003b2;arrestin2 recruitment was lower in untreated CB<sub>2</sub>&#x02010;expressing cells transfected with 0.10, 0.25, or 0.50&#x02009;&#x003bc;g OX<sub>1</sub> compared to non&#x02010;transfected cells; similarly, &#x003b2;arrestin2 recruitment was lower in CB<sub>2</sub>&#x02010;expressing cells transfected with 0.10&#x02009;&#x003bc;g OX<sub>1</sub> compared to non&#x02010;transfected cells that received 0.1% DMSO in PBS (Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4C</xref>). The potency of CP55,940 did not appear to follow a specific trend as a function of the amount of OX<sub>1</sub> transfected (Table&#x000a0;<xref rid="prp270078-tbl-0003" ref-type="table">3</xref>). However, the efficacy of CP55,940 did increase as the level of OX<sub>1</sub> increased up to 0.25&#x02009;&#x003bc;g OX<sub>1</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4D</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0003" ref-type="table">3</xref>). At 0.50&#x02009;&#x003bc;g OX<sub>1</sub>, the efficacy of CP55,940 was not statistically different from that of non&#x02010;transfected cells (Table&#x000a0;<xref rid="prp270078-tbl-0003" ref-type="table">3</xref>). Thus, our system may be oversaturated at plasmid levels above 0.25&#x02009;&#x003bc;g OX<sub>1</sub>. These data suggest that OX<sub>1</sub> enhances CP55,940&#x02010;dependent &#x003b2;arrestin2 recruitment while reducing &#x003b2;arrestin2 recruitment in the absence of a CB<sub>2</sub> agonist.</p><fig position="float" fig-type="FIGURE" id="prp270078-fig-0004"><label>FIGURE 4</label><caption><p>CB<sub>2</sub>&#x02010;dependent inhibition of cAMP and &#x003b2;arrestin2 recruitment in CB<sub>2</sub>&#x02010;OX<sub>1</sub> cells. CHO cells stably expressing CB<sub>2</sub> and transiently expressing OX<sub>1</sub> were treated with 10&#x02009;&#x003bc;M FSK and 0.1&#x02009;nM&#x02013;10&#x02009;&#x003bc;M CP55,940 for 90&#x02009;min to measure cAMP inhibition (A, B) or 0.1&#x02009;nM&#x02013;10&#x02009;&#x003bc;M CP55,940 for 90&#x02009;min to measure &#x003b2;arrestin2 recruitment (C, D). Data were fit to a 4&#x02010;parameter non&#x02010;linear regression and are represented as fold over vehicle. Data are mean&#x02009;&#x000b1;&#x02009;SEM from <italic toggle="yes">n</italic>&#x02009;=&#x02009;4&#x02013;8 independent experiments performed in triplicate. *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001, ****<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 within treatment between groups; <sup>##</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>###</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 within groups between treatments as determined by two&#x02010;way ANOVA followed by Tukey's post hoc test.</p></caption><graphic xlink:href="PRP2-13-e70078-g002" position="anchor" id="jats-graphic-9"/></fig><table-wrap position="float" id="prp270078-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>CB<sub>2</sub>&#x02010;dependent inhibition of cAMP and recruitment of &#x003b2;arrestin2 in CB<sub>2</sub>&#x02010;OX<sub>1</sub> cells.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">[OX<sub>1</sub>] (&#x003bc;g)</th><th align="center" colspan="3" valign="bottom" rowspan="1">cAMP</th><th align="center" colspan="3" valign="bottom" rowspan="1">&#x003b2;arrestin2</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">pEC<sub>50</sub> (nM)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max</sub> (Fold)<xref rid="prp270078-note-0018" ref-type="table-fn">
<sup>b</sup>
</xref>
</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hill slope</th><th align="center" valign="bottom" rowspan="1" colspan="1">pEC<sub>50</sub> (nM)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max</sub> (Fold)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hill slope</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="center" valign="top" rowspan="1" colspan="1">8.0&#x02009;&#x000b1;&#x02009;0.62 (10)<xref rid="prp270078-note-0017" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.87&#x02009;&#x000b1;&#x02009;0.02<xref rid="prp270078-note-0017" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1<xref rid="prp270078-note-0017" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">6.9&#x02009;&#x000b1;&#x02009;0.42 (120)</td><td align="center" valign="top" rowspan="1" colspan="1">2.3&#x02009;&#x000b1;&#x02009;0.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.79&#x02009;&#x000b1;&#x02009;0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">n.c.</td><td align="center" valign="top" rowspan="1" colspan="1">0.96&#x02009;&#x000b1;&#x02009;0.05<xref rid="prp270078-note-0016" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">n.c.</td><td align="center" valign="top" rowspan="1" colspan="1">7.3&#x02009;&#x000b1;&#x02009;0.17 (50)</td><td align="center" valign="top" rowspan="1" colspan="1">2.9&#x02009;&#x000b1;&#x02009;0.13<xref rid="prp270078-note-0016" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.80&#x02009;&#x000b1;&#x02009;0.22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">n.c</td><td align="center" valign="top" rowspan="1" colspan="1">0.94&#x02009;&#x000b1;&#x02009;0.07</td><td align="center" valign="top" rowspan="1" colspan="1">n.c.</td><td align="center" valign="top" rowspan="1" colspan="1">6.9&#x02009;&#x000b1;&#x02009;0.10 (130)</td><td align="center" valign="top" rowspan="1" colspan="1">3.0&#x02009;&#x000b1;&#x02009;0.11<xref rid="prp270078-note-0016" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.0&#x02009;&#x000b1;&#x02009;0.25</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="center" valign="top" rowspan="1" colspan="1">n.c</td><td align="center" valign="top" rowspan="1" colspan="1">0.92&#x02009;&#x000b1;&#x02009;0.04</td><td align="center" valign="top" rowspan="1" colspan="1">n.c.</td><td align="center" valign="top" rowspan="1" colspan="1">7.4&#x02009;&#x000b1;&#x02009;0.29 (38)</td><td align="center" valign="top" rowspan="1" colspan="1">2.5&#x02009;&#x000b1;&#x02009;0.18</td><td align="center" valign="top" rowspan="1" colspan="1">0.60&#x02009;&#x000b1;&#x02009;0.25</td></tr></tbody></table><table-wrap-foot id="prp270078-ntgp-0004"><fn id="prp270078-note-0014"><p>
<italic toggle="yes">Note:</italic> Data were fit to a 4&#x02010;parameter non&#x02010;linear regression to estimate potency (pEC<sub>50</sub>) and efficacy (<italic toggle="yes">E</italic>
<sub>max</sub>) values. Data are expressed as mean&#x02009;&#x000b1;&#x02009;SEM. <italic toggle="yes">n</italic>&#x02009;=&#x02009;4&#x02013;8 independent experiments performed in triplicate. If potency could not be estimated (i.e., &#x0003c;&#x02009;0.1&#x02009;nM), then <italic toggle="yes">E</italic>
<sub>max</sub> is reported as the mean of the greatest response observed. Statistical analyses were by one&#x02010;way ANOVA followed by Tukey's post hoc test. Data presented in the Table relate to Figure&#x000a0;<xref rid="prp270078-fig-0004" ref-type="fig">4</xref>.</p></fn><fn id="prp270078-note-0015"><p>Abbreviation: n.c&#x02014;not converged.</p></fn><fn id="prp270078-note-0016"><label>*</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05 relative to CP55,940.</p></fn><fn id="prp270078-note-0017"><label>
<sup>a</sup>
</label><p>When fit to a 4&#x02010;parameter model, pEC<sub>50</sub> and Hill Slope could not be accurately estimated, data in table are for a Hill Slope constrained to 1.</p></fn><fn id="prp270078-note-0018"><label>
<sup>b</sup>
</label><p>For data where no clear CRC was observed, <italic toggle="yes">E</italic>
<sub>max</sub> represents the lowest value observed.</p></fn></table-wrap-foot></table-wrap></sec><sec id="prp270078-sec-0017"><label>3.5</label><title>Modulation of <styled-content style="fixed-case" toggle="no">cAMP</styled-content> and &#x003b2;arrestin2 Recruitment in <styled-content style="fixed-case" toggle="no">CB<sub>2</sub>
</styled-content>&#x02010;<styled-content style="fixed-case" toggle="no">OX<sub>2</sub>
</styled-content> Transfected Cells</title><p>No statistical differences in cAMP response were observed among untreated cells (Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5A</xref>). Ten micrometer FSK (in 0.1% DMSO with PBS) produced an increase in cAMP response that was significant in cells that were transfected with 0.25 or 0.50&#x02009;&#x003bc;g OX<sub>2</sub> compared to untreated cells (Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5A</xref>). As elsewhere, CRC data in Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5B,D</xref> were constrained for <italic toggle="yes">E</italic>
<sub>min</sub>&#x02009;=&#x02009;1 to allow for comparisons of potency and efficacy following CP55,940 treatment. Data for cells not expressing OX<sub>2</sub> (i.e., 0.0&#x02009;&#x003bc;g) or transfected with 0.10&#x02009;&#x003bc;g OX<sub>2</sub> could not be fit to a 4&#x02010;parameter model as the Hill slope was too variable (Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5B</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0004" ref-type="table">4</xref>). The CRC for cells that were not transfected with OX<sub>2</sub> had a relatively low goodness of fit (<italic toggle="yes">R</italic>
<sup>2</sup>&#x02009;=&#x02009;0.21); and these data should be interpreted with that caveat in mind. CP55,940's efficacy significantly increased in all transfection groups in an OX<sub>2</sub> amount&#x02010;dependent order (Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5B</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0004" ref-type="table">4</xref>). These data suggest that OX<sub>2</sub> facilitates CB<sub>2</sub>&#x02010;dependent cAMP inhibition in CP55,940&#x02010;treated cells. In untreated cells, the presence of OX<sub>2</sub> led to a significant increase in &#x003b2;arrestin2 recruitment in cells transfected with 0.10 and 0.25&#x02009;&#x003bc;g OX<sub>2</sub> but not in cells transfected with 0.50&#x02009;&#x003bc;g OX<sub>2</sub>, which may suggest that our system is oversaturated at plasmid levels above 0.25&#x02009;&#x003bc;g OX<sub>2</sub> (Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5C</xref>). In cells that received 0.1% DMSO with PBS, a similar effect was seen, in which cells transfected with 0.10 and 0.25&#x02009;&#x003bc;g OX<sub>2</sub> exhibited significant increases in &#x003b2;arrestin2 recruitment (Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5C</xref>). Data for cells transfected with 0.10&#x02009;&#x003bc;g OX<sub>2</sub> could not be fit to a 4&#x02010;parameter model as the Hill slope was too variable (Table&#x000a0;<xref rid="prp270078-tbl-0004" ref-type="table">4</xref>). CP55,940's potency was improved in the presence of 0.25&#x02009;&#x003bc;g OX<sub>2</sub>, although its efficacy decreased in cells transfected with OX<sub>2</sub>, with only 0.10&#x02009;&#x003bc;g being significant (Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5D</xref> and Table&#x000a0;<xref rid="prp270078-tbl-0004" ref-type="table">4</xref>). Overall, OX<sub>2</sub> enhanced basal CB<sub>2</sub>&#x02010;mediated &#x003b2;arrestin2 recruitment, but CP55,940's potency and efficacy at CB<sub>2</sub> were generally reduced when OX<sub>2</sub> was present.</p><fig position="float" fig-type="FIGURE" id="prp270078-fig-0005"><label>FIGURE 5</label><caption><p>CB<sub>2</sub>&#x02010;dependent inhibition of cAMP and &#x003b2;arrestin2 recruitment in CB<sub>2</sub>&#x02010;OX<sub>2</sub> cells. CHO cells stably expressing CB<sub>2</sub> and transiently expressing OX<sub>2</sub> were treated with 10&#x02009;&#x003bc;M FSK and 0.1&#x02009;nM&#x02014;10&#x02009;&#x003bc;M CP55,940 for 90&#x02009;min to measure cAMP inhibition (A, B) or 0.1&#x02009;nM&#x02014;10&#x02009;&#x003bc;M CP55,940 for 90&#x02009;min to measure &#x003b2;arrestin2 recruitment (C, D). Data were fit to a 4&#x02010;parameter non&#x02010;linear regression and are represented as fold over vehicle. Data are mean&#x02009;&#x000b1;&#x02009;SEM from <italic toggle="yes">n</italic>&#x02009;=&#x02009;4&#x02013;8 independent experiments performed in triplicate. *<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.05, **<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, ***<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 within treatment between groups; <sup>##</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01, <sup>###</sup>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001 within groups between treatments, as determined by two&#x02010;way ANOVA followed by Tukey's <italic toggle="yes">post hoc</italic> test.</p></caption><graphic xlink:href="PRP2-13-e70078-g001" position="anchor" id="jats-graphic-11"/></fig><table-wrap position="float" id="prp270078-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>CB<sub>2</sub>&#x02010;dependent inhibition of cAMP and recruitment of &#x003b2;arrestin2 in CB<sub>2</sub>&#x02010;OX<sub>2</sub> cells.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="bottom" colspan="1">[OX<sub>2</sub>] (&#x003bc;g)</th><th align="center" colspan="3" valign="bottom" rowspan="1">cAMP</th><th align="center" colspan="3" valign="bottom" rowspan="1">&#x003b2;arrestin2</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="bottom" rowspan="1" colspan="1">pEC<sub>50</sub> (nM)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max</sub> (Fold)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hill slope</th><th align="center" valign="bottom" rowspan="1" colspan="1">pEC<sub>50</sub> (nM)</th><th align="center" valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">E</italic>
<sub>max</sub> (Fold)</th><th align="center" valign="bottom" rowspan="1" colspan="1">Hill slope</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">0.00</td><td align="center" valign="top" rowspan="1" colspan="1">8.0&#x02009;&#x000b1;&#x02009;0.62 (10)<xref rid="prp270078-note-0023" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.87&#x02009;&#x000b1;&#x02009;0.02<xref rid="prp270078-note-0023" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1<xref rid="prp270078-note-0023" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">6.9&#x02009;&#x000b1;&#x02009;0.42 (120)</td><td align="center" valign="top" rowspan="1" colspan="1">2.3&#x02009;&#x000b1;&#x02009;0.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.79&#x02009;&#x000b1;&#x02009;0.58</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.10</td><td align="center" valign="top" rowspan="1" colspan="1">7.8&#x02009;&#x000b1;&#x02009;0.26 (17)<xref rid="prp270078-note-0023" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">0.75&#x02009;&#x000b1;&#x02009;0.02<xref rid="prp270078-note-0020" ref-type="table-fn">**</xref>, <xref rid="prp270078-note-0023" ref-type="table-fn">,<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1<xref rid="prp270078-note-0023" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">8.3&#x02009;&#x000b1;&#x02009;0.51 (5.0)<xref rid="prp270078-note-0023" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.3&#x02009;&#x000b1;&#x02009;0.04<xref rid="prp270078-note-1020" ref-type="table-fn">*</xref>,<xref rid="prp270078-note-0023" ref-type="table-fn">
<sup>a</sup>
</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1<xref rid="prp270078-note-0023" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="center" valign="top" rowspan="1" colspan="1">7.8&#x02009;&#x000b1;&#x02009;0.17 (16)</td><td align="center" valign="top" rowspan="1" colspan="1">0.76&#x02009;&#x000b1;&#x02009;0.02<xref rid="prp270078-note-0020" ref-type="table-fn">**</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.2&#x02009;&#x000b1;&#x02009;0.56</td><td align="center" valign="top" rowspan="1" colspan="1">9.3&#x02009;&#x000b1;&#x02009;3.2 (0.45)<xref rid="prp270078-note-1020" ref-type="table-fn">*</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">1.8&#x02009;&#x000b1;&#x02009;0.20</td><td align="center" valign="top" rowspan="1" colspan="1">0.36&#x02009;&#x000b1;&#x02009;0.45</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">0.50</td><td align="center" valign="top" rowspan="1" colspan="1">7.9&#x02009;&#x000b1;&#x02009;0.20 (11)</td><td align="center" valign="top" rowspan="1" colspan="1">0.68&#x02009;&#x000b1;&#x02009;0.03<xref rid="prp270078-note-0022" ref-type="table-fn">****</xref>
</td><td align="center" valign="top" rowspan="1" colspan="1">&#x02212;1.2&#x02009;&#x000b1;&#x02009;0.78</td><td align="center" valign="top" rowspan="1" colspan="1">8.3&#x02009;&#x000b1;&#x02009;0.32 (4.9)</td><td align="center" valign="top" rowspan="1" colspan="1">1.4&#x02009;&#x000b1;&#x02009;0.03</td><td align="center" valign="top" rowspan="1" colspan="1">1.2&#x02009;&#x000b1;&#x02009;0.86</td></tr></tbody></table><table-wrap-foot id="prp270078-ntgp-0005"><fn id="prp270078-note-0019"><p>
<italic toggle="yes">Note:</italic> Data were fit to a 4&#x02010;parameter non&#x02010;linear regression to estimate potency (pEC<sub>50</sub>) and efficacy (<italic toggle="yes">E</italic>
<sub>max</sub>) values. Data are expressed as mean&#x02009;&#x000b1;&#x02009;SEM. <italic toggle="yes">n</italic>&#x02009;=&#x02009;4&#x02013;8 independent experiments performed in triplicate. Statistical analyses were by one&#x02010;way ANOVA followed by Tukey's post hoc test. Data presented in the Table relate to Figure&#x000a0;<xref rid="prp270078-fig-0005" ref-type="fig">5</xref>.</p></fn><fn id="prp270078-note-1020"><label>*</label><p>
<italic toggle="yes">p</italic> &#x0003c; 0.05.</p></fn><fn id="prp270078-note-0020"><label>**</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.01.</p></fn><fn id="prp270078-note-0021"><label>***</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.001.</p></fn><fn id="prp270078-note-0022"><label>****</label><p>
<italic toggle="yes">p</italic>&#x02009;&#x0003c;&#x02009;0.0001 relative to CP55,940.</p></fn><fn id="prp270078-note-0023"><label>
<sup>a</sup>
</label><p>When fit to a 4&#x02010;parameter model, pEC<sub>50</sub> and Hill Slope could not be accurately estimated, data in table are for a Hill Slope constrained to 1.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="prp270078-sec-0018"><label>4</label><title>Discussion</title><p>CB<sub>1</sub> interacts with various serotonin, somatostatin, dopamine, opioid, adenosine, and angiotensin receptors, as well as the orphan receptor <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=109" ext-link-type="uri">GPR55</ext-link> [<xref rid="prp270078-bib-0031" ref-type="bibr">31</xref>, <xref rid="prp270078-bib-0032" ref-type="bibr">32</xref>, <xref rid="prp270078-bib-0033" ref-type="bibr">33</xref>, <xref rid="prp270078-bib-0034" ref-type="bibr">34</xref>, <xref rid="prp270078-bib-0035" ref-type="bibr">35</xref>, <xref rid="prp270078-bib-0036" ref-type="bibr">36</xref>]. Some of these interactions are known to modulate receptor activity. For example, CB<sub>1</sub> preferentially couples to G&#x003b1;<sub>s</sub> G proteins instead of G&#x003b1;<sub>i/o</sub> G proteins when co&#x02010;expressed with the dopamine <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=215" ext-link-type="uri">D<sub>2</sub>
</ext-link> receptor [<xref rid="prp270078-bib-0037" ref-type="bibr">37</xref>]. Much less is known about CB<sub>2</sub>'s interactions with other GPCRs, though previous studies suggest CB<sub>2</sub> interacts with GPR55, serotonin, and chemokine receptors [<xref rid="prp270078-bib-0038" ref-type="bibr">38</xref>, <xref rid="prp270078-bib-0039" ref-type="bibr">39</xref>, <xref rid="prp270078-bib-0040" ref-type="bibr">40</xref>, <xref rid="prp270078-bib-0041" ref-type="bibr">41</xref>].</p><p>Data from numerous studies now suggest that crosstalk exists between the endocannabinoid and orexinergic systems reviewed in [<xref rid="prp270078-bib-0012" ref-type="bibr">12</xref>]. It is critical to clarify how these complex biological systems interact with one another, considering their shared anatomical distribution and what implications these interactions have on physiological processes regulated by these systems. Our results demonstrate that the introduction of OX<sub>1</sub> or OX<sub>2</sub> can alter the pharmacological properties (i.e., efficacy, potency) of the agonist CP55,940 at CB<sub>1</sub> and CB<sub>2</sub>. For CB<sub>1</sub>, the presence of OX<sub>1</sub> appeared to increase the efficacy of CP55,940&#x02010;dependent cAMP inhibition and conversely decrease &#x003b2;arrestin2 recruitment, with no clear effect on potency; whereas the presence of OX<sub>2</sub> augmented the efficacy and potency of CP55,940&#x02010;dependent cAMP inhibition <italic toggle="yes">and</italic> the efficacy of &#x003b2;arrestin2 recruitment. For both CB<sub>2</sub>&#x02010;OX<sub>1</sub> and CB<sub>2</sub>&#x02010;OX<sub>2</sub> pairings, the presence of OX<sub>1</sub> or OX<sub>2</sub> appeared to decrease the efficacy of CP55,940&#x02010;dependent cAMP inhibition; whereas for &#x003b2;arrestin2 the CB<sub>2</sub>&#x02010;OX<sub>1</sub> pairing was associated with greater &#x003b2;arrestin2 recruitment in the presence of CP55, 940 and the CB<sub>2</sub>&#x02010;OX<sub>2</sub> pairing was associated with less &#x003b2;arrestin2 recruitment. These data suggest that the form of interaction between CB<sub>2</sub>&#x02010;OX<sub>1</sub> or CB<sub>2</sub>&#x02010;OX<sub>2</sub> and the G&#x003b1;<sub>i/o</sub> and &#x003b2;arrestin2 recruitment pathways differs from that of CB<sub>1</sub> with OX<sub>1</sub> or OX<sub>2</sub> for that matter. Such differences in receptor interactivity warrant further examination in future studies to determine what effectors&#x02014;whether at the receptor or downstream&#x02014;differentiate each pairing and gain mechanistic insight into receptor crosstalk.</p><p>As with other studies exploring GPCR signaling and cross&#x02010;talk, a major limitation is that our results were obtained in a heterologous system [<xref rid="prp270078-bib-0019" ref-type="bibr">19</xref>, <xref rid="prp270078-bib-0042" ref-type="bibr">42</xref>]. Considering that our in&#x000a0;vitro model consisted of CHO&#x02010;K1 cells overexpressing human GPCRs, these results may not be reflective of the activity of these receptors when expressed in native tissues [<xref rid="prp270078-bib-0043" ref-type="bibr">43</xref>, <xref rid="prp270078-bib-0044" ref-type="bibr">44</xref>]. In our experimental setup, the chosen vehicles (e.g., 0.1% DMSO in PBS) produced changes in cAMP response or &#x003b2;arrestin2 recruitment that were sometimes unexpectedly statistically significant (e.g., Figures&#x000a0;<xref rid="prp270078-fig-0002" ref-type="fig">2C</xref> and <xref rid="prp270078-fig-0003" ref-type="fig">3C</xref>). Although the biological significance of these changes is unclear, we felt it important to include those data to showcase the real potential effects vehicle solvents can have on system measurements. Such systems are inherently variable, and here we display that variability as directly as possible. In addition, our study examined a single timepoint of receptor signaling, 90&#x02009;min after CP55,940 treatment. This timepoint was optimized for the &#x003b2;arrestin2 assay and then matched in the cAMP inhibition assay. However, it is possible that receptor desensitization occurred during that time or that some signal was lost in the cAMP assay due to the actions of phosphodiesterases. Moreover, our study did not account for the potential activity of endogenous cannabinoids such as 2&#x02010;AG [<xref rid="prp270078-bib-0020" ref-type="bibr">20</xref>, <xref rid="prp270078-bib-0021" ref-type="bibr">21</xref>]. Thus, we do not know if these effects detected in&#x000a0;vitro would also be present in&#x000a0;vivo. It will be necessary to establish that these receptor pairings are co&#x02010;expressed on the same cells or tissues in&#x000a0;vivo [<xref rid="prp270078-bib-0018" ref-type="bibr">18</xref>]. Even if these GPCRs are co&#x02010;expressed and present in&#x000a0;vivo, we will need to assess whether these receptors engage in crosstalk and/or heterodimerization [<xref rid="prp270078-bib-0045" ref-type="bibr">45</xref>]. Previous work from our research group using C57BL/6 mice found that OX<sub>1</sub> antagonism increases CB<sub>1</sub>&#x02010;OX<sub>1</sub>, but not CB<sub>1</sub>&#x02010;OX<sub>2</sub>, colocalization in the ventral striatum, and that this colocalization is responsible for the observed increase in catalepsy in mice co&#x02010;treated with CP55,940 and the dual orexin receptor antagonist (DORA) <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9304" ext-link-type="uri">TCS&#x02010;1102</ext-link> [<xref rid="prp270078-bib-0046" ref-type="bibr">46</xref>].</p><p>While this study revealed that OX<sub>1</sub> and OX<sub>2</sub> can alter CB<sub>1</sub>&#x02010;mediated and CB<sub>2</sub>&#x02010;mediated signaling, our experiments used CHO&#x02010;K1 cells that were transiently transfected with OX<sub>1</sub> or OX<sub>2</sub>. Transfection efficiency in these cells ranged from 19% to 75% but was higher than cells that were exposed to only Lipofectamine 3000 and not transfected with plasmid DNA (i.e., &#x02018;mock' transfected). Increasing amounts of either receptor did produce a response different from mock&#x02010;transfected controls. Additionally, we did not establish the physical interaction of these receptors, which has been done by other groups in similar model systems already [<xref rid="prp270078-bib-0012" ref-type="bibr">12</xref>]. We aim to assess changes in receptor trafficking, co&#x02010;localization, and expression via immunohistochemical microscopy and western blotting with in&#x000a0;vitro and ex&#x000a0;vivo model systems in future studies. It is possible that the observed effect of orexin receptors on cannabinoid receptor signaling is a result of a functional interaction and not evidence of receptor dimerization per se [<xref rid="prp270078-bib-0022" ref-type="bibr">22</xref>]. Bioluminescence resonance energy transfer (BRET) and/or fluorescence resonance energy transfer (FRET) techniques could also be used to investigate physical interactions between these receptors [<xref rid="prp270078-bib-0033" ref-type="bibr">33</xref>]. However, such experiments would only establish whether heterodimer formation between cannabinoid and orexin receptors is possible and not if such complexes alter signal transduction at the plasma membrane [<xref rid="prp270078-bib-0023" ref-type="bibr">23</xref>, <xref rid="prp270078-bib-0031" ref-type="bibr">31</xref>].</p><p>It is important to determine the specific physiological roles of cannabinoid&#x02010;orexin receptor crosstalk and this will require tools which probe those interactions (e.g., heterodimer&#x02010;specific agonists and antagonists) [<xref rid="prp270078-bib-0033" ref-type="bibr">33</xref>]. The development of bitopic or bivalent ligands targeting cannabinoid&#x02010;orexin heterodimers will be of great use to study these interactions in&#x000a0;vivo and to determine their significance in physiological or pathological conditions [<xref rid="prp270078-bib-0007" ref-type="bibr">7</xref>, <xref rid="prp270078-bib-0047" ref-type="bibr">47</xref>]. Such ligands consist of two pharmacophores joined together by a linker molecule allowing them to simultaneously interact with both receptors of the heterodimer [<xref rid="prp270078-bib-0006" ref-type="bibr">6</xref>, <xref rid="prp270078-bib-0042" ref-type="bibr">42</xref>]. A series of bivalent ligands targeting CB<sub>1</sub> and OX<sub>1</sub> has been previously developed using SR141716 and <ext-link xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2886" ext-link-type="uri">ACT&#x02010;078573</ext-link> pharmacophores. However, while all ligands in this series were potent at CB<sub>1</sub>, most had poor activity at OX<sub>1</sub>, demonstrating the need for bivalent ligands with improved pharmacological properties at both receptors of the heterodimer [<xref rid="prp270078-bib-0007" ref-type="bibr">7</xref>].</p><p>In conclusion, our study revealed that orexin receptors affect agonist&#x02010;dependent signaling at the cannabinoid receptors. Orexin receptors generally enhanced cannabinoid receptor&#x02010;mediated cAMP inhibition while they may increase or decrease cannabinoid receptor&#x02010;mediated &#x003b2;arrestin2 recruitment. The effects on cannabinoid receptor signaling by the presence of orexin receptors observed here require further evaluation regarding receptor localization and expression both in&#x000a0;vitro and in&#x000a0;vivo.</p></sec><sec id="prp270078-sec-0019"><title>Author Contributions</title><p>K.A.M. designed and executed experiments, analyzed data, and contributed to the writing and editing of the manuscript. R.B.L. analyzed data and contributed to the writing and editing of the manuscript.</p></sec><sec sec-type="COI-statement" id="prp270078-sec-0020"><title>Conflicts of Interest</title><p>R.B.L. served on the Scientific Advisory Board for Shackleford Pharma Inc. and has consulted in medico&#x02010;legal cases concerning cannabis and cannabinoids. None of these entities had any actual or perceived input into the design or output of this study. K.A.M. declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflicts of interest.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="prp270078-supitem-0001" position="float" content-type="local-data"><caption><p>
Data S1.
</p></caption><media xlink:href="PRP2-13-e70078-s001.docx"/></supplementary-material></sec></body><back><sec sec-type="data-availability" id="prp270078-sec-0022"><title>Data Availability Statement</title><p>The authors declare that all the data supporting the findings of this study are available within the paper and its Supplemental Data. Raw data used for this study are available at the Dryad repository (DOI: <ext-link xlink:href="https://doi.org/10.5061/dryad.0cfxpnwcq" ext-link-type="uri">10.5061/dryad.0cfxpnwcq</ext-link>).</p></sec><ref-list content-type="cited-references" id="prp270078-bibl-0001"><title>References</title><ref id="prp270078-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="prp270078-cit-0001">
<string-name>
<given-names>J.</given-names>
<surname>Petersen</surname>
</string-name>, <string-name>
<given-names>S. C.</given-names>
<surname>Wright</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Rodr&#x000ed;guez</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Agonist&#x02010;Induced Dimer Dissociation as a Macromolecular Step in G Protein&#x02010;Coupled Receptor Signaling</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>8</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>226</fpage>, <pub-id pub-id-type="doi">10.1038/s41467-017-00253-9</pub-id>.</mixed-citation></ref><ref id="prp270078-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="prp270078-cit-0002">
<string-name>
<given-names>W. M.</given-names>
<surname>Oldham</surname>
</string-name> and <string-name>
<given-names>H. E.</given-names>
<surname>Hamm</surname>
</string-name>, &#x0201c;<article-title>Heterotrimeric G Protein Activation by G&#x02010;Protein&#x02010;Coupled Receptors</article-title>,&#x0201d; <source>Nature Reviews. Molecular Cell Biology</source>
<volume>9</volume>, no. <issue>1</issue> (<year>2008</year>): <fpage>60</fpage>&#x02013;<lpage>71</lpage>, <pub-id pub-id-type="doi">10.1038/nrm2299</pub-id>.<pub-id pub-id-type="pmid">18043707</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="prp270078-cit-0003">
<string-name>
<given-names>T.</given-names>
<surname>Ullmann</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gienger</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Budzinski</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Homobivalent Dopamine D2 Receptor Ligands Modulate the Dynamic Equilibrium of D2Monomers and Homo&#x02010; And Heterodimers</article-title>,&#x0201d; <source>ACS Chemical Biology</source>
<volume>16</volume>, no. <issue>2</issue> (<year>2021</year>): <fpage>371</fpage>&#x02013;<lpage>379</lpage>, <pub-id pub-id-type="doi">10.1021/acschembio.0c00895</pub-id>.<pub-id pub-id-type="pmid">33435665</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="prp270078-cit-0004">
<string-name>
<given-names>G.</given-names>
<surname>Milligan</surname>
</string-name>, &#x0201c;<article-title>G Protein&#x02010;Coupled Receptor Hetero&#x02010;Dimerization: Contribution to Pharmacology and Function</article-title>,&#x0201d; <source>British Journal of Pharmacology</source>
<volume>158</volume>, no. <issue>1</issue> (<year>2009</year>): <fpage>5</fpage>&#x02013;<lpage>14</lpage>, <pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00169.x</pub-id>.<pub-id pub-id-type="pmid">19309353</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="prp270078-cit-0005">
<string-name>
<given-names>X. J.</given-names>
<surname>He</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Patel</surname>
</string-name>, <string-name>
<given-names>C. E.</given-names>
<surname>Weiss</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>B. L.</given-names>
<surname>Bloodgood</surname>
</string-name>, and <string-name>
<given-names>M. R.</given-names>
<surname>Banghart</surname>
</string-name>, &#x0201c;<article-title>Convergent, Functionally Independent Signaling by Mu and Delta Opioid Receptors in Hippocampal Parvalbumin Interneurons</article-title>,&#x0201d; <source>eLife</source>
<volume>10</volume> (<year>2021</year>): <elocation-id>e69746</elocation-id>, <pub-id pub-id-type="doi">10.7554/eLife.69746</pub-id>.<pub-id pub-id-type="pmid">34787079</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="prp270078-cit-0006">
<string-name>
<given-names>H.</given-names>
<surname>Hubner</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Schellhorn</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Gienger</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Structure&#x02010;Guided Development of Heterodimer&#x02010;Selective GPCR Ligands</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>7</volume> (<year>2016</year>): <fpage>1</fpage>&#x02013;<lpage>12</lpage>, <pub-id pub-id-type="doi">10.1038/ncomms12298</pub-id>.</mixed-citation></ref><ref id="prp270078-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="prp270078-cit-0007">
<string-name>
<given-names>D. A.</given-names>
<surname>Perrey</surname>
</string-name>, <string-name>
<given-names>B. P.</given-names>
<surname>Gilmour</surname>
</string-name>, <string-name>
<given-names>B. F.</given-names>
<surname>Thomas</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Zhang</surname>
</string-name>, &#x0201c;<article-title>Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers</article-title>,&#x0201d; <source>ACS Medicinal Chemistry Letters</source>
<volume>5</volume>, no. <issue>6</issue> (<year>2014</year>): <fpage>634</fpage>&#x02013;<lpage>638</lpage>, <pub-id pub-id-type="doi">10.1021/ml4004759</pub-id>.<pub-id pub-id-type="pmid">24944734</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="prp270078-cit-0008">
<string-name>
<given-names>R. G.</given-names>
<surname>Pertwee</surname>
</string-name>, &#x0201c;<article-title>The Pharmacology of Cannabinoid Receptors and Their Ligands: An Overview</article-title>,&#x0201d; <source>International Journal of Obesity</source>
<volume>30</volume> (<year>2006</year>): <fpage>S13</fpage>&#x02013;<lpage>S18</lpage>, <pub-id pub-id-type="doi">10.1038/sj.ijo.0803272</pub-id>.<pub-id pub-id-type="pmid">16570099</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="prp270078-cit-0009">
<string-name>
<given-names>H. C.</given-names>
<surname>Lu</surname>
</string-name> and <string-name>
<given-names>K.</given-names>
<surname>Mackie</surname>
</string-name>, &#x0201c;<article-title>An Introduction to the Endogenous Cannabinoid System</article-title>,&#x0201d; <source>Biological Psychiatry</source>
<volume>79</volume>, no. <issue>7</issue> (<year>2016</year>): <fpage>516</fpage>&#x02013;<lpage>525</lpage>, <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.07.028.An</pub-id>.<pub-id pub-id-type="pmid">26698193</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="prp270078-cit-0010">
<string-name>
<given-names>T.</given-names>
<surname>Sakurai</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Amemiya</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Ishii</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein&#x02010;Coupled Receptors That Regulate Feeding Behavior</article-title>,&#x0201d; <source>Cell</source>
<volume>92</volume>, no. <issue>4</issue> (<year>1998</year>): <fpage>573</fpage>&#x02013;<lpage>585</lpage>, <pub-id pub-id-type="doi">10.1016/S0092-8674(00)80949-6</pub-id>.<pub-id pub-id-type="pmid">9491897</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="prp270078-cit-0011">
<string-name>
<given-names>M.</given-names>
<surname>Mieda</surname>
</string-name> and <string-name>
<given-names>M.</given-names>
<surname>Yanagisawa</surname>
</string-name>, &#x0201c;<article-title>Sleep, Feeding, and Neuropeptides: Roles of Orexins and Orexin Receptors</article-title>,&#x0201d; <source>Current Opinion in Neurobiology</source>
<volume>12</volume>, no. <issue>3</issue> (<year>2002</year>): <fpage>339</fpage>&#x02013;<lpage>345</lpage>, <pub-id pub-id-type="doi">10.1016/S0959-4388(02)00331-8</pub-id>.<pub-id pub-id-type="pmid">12049942</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="prp270078-cit-0012">
<string-name>
<given-names>&#x000c1;.</given-names>
<surname>Flores</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Maldonado</surname>
</string-name>, and <string-name>
<given-names>F.</given-names>
<surname>Berrendero</surname>
</string-name>, &#x0201c;<article-title>Cannabinoid&#x02010;Hypocretin Cross&#x02010;Talk in the Central Nervous System: What We Know So Far</article-title>,&#x0201d; <source>Frontiers in Neuroscience</source>
<volume>7</volume> (<year>2013</year>): <elocation-id>256</elocation-id>, <pub-id pub-id-type="doi">10.3389/fnins.2013.00256</pub-id>.<pub-id pub-id-type="pmid">24391536</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="prp270078-cit-0013">
<string-name>
<given-names>R. T.</given-names>
<surname>Dorsam</surname>
</string-name> and <string-name>
<given-names>J. S.</given-names>
<surname>Gutkind</surname>
</string-name>, &#x0201c;<article-title>G&#x02010;Protein&#x02010;Coupled Receptors and Cancer</article-title>,&#x0201d; <source>Nature Reviews. Cancer</source>
<volume>7</volume>, no. <issue>2</issue> (<year>2007</year>): <fpage>79</fpage>&#x02013;<lpage>94</lpage>, <pub-id pub-id-type="doi">10.1038/nrc2069</pub-id>.<pub-id pub-id-type="pmid">17251915</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="prp270078-cit-0014">
<string-name>
<given-names>N.</given-names>
<surname>Tsujino</surname>
</string-name> and <string-name>
<given-names>T.</given-names>
<surname>Sakurai</surname>
</string-name>, &#x0201c;<article-title>Orexin/Hypocretin: A Neuropeptide at the Interface of Sleep, Energy Homeostasis, and Reward System</article-title>,&#x0201d; <source>Pharmacological Reviews</source>
<volume>61</volume>, no. <issue>2</issue> (<year>2009</year>): <fpage>162</fpage>&#x02013;<lpage>176</lpage>, <pub-id pub-id-type="doi">10.1124/pr.109.001321</pub-id>.<pub-id pub-id-type="pmid">19549926</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="prp270078-cit-0015">
<string-name>
<given-names>K.</given-names>
<surname>Mackie</surname>
</string-name>, &#x0201c;<article-title>Cannabinoid Receptors: Where They Are and What They Do</article-title>,&#x0201d; <source>Journal of Neuroendocrinology</source>
<volume>20</volume> (<year>2008</year>): <fpage>10</fpage>&#x02013;<lpage>14</lpage>, <pub-id pub-id-type="doi">10.1111/j.1365-2826.2008.01671.x</pub-id>.<pub-id pub-id-type="pmid">18426493</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="prp270078-cit-0016">
<string-name>
<given-names>N.</given-names>
<surname>Forte</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Boccella</surname>
</string-name>, <string-name>
<given-names>L. A.</given-names>
<surname>Tunisi</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cristino Orexin&#x02010;A and Endocannabinoids Are Involved in Obesity&#x02010;Associated Alteration of Hippocampal Neurogenesis, Plasticity, and Episodic Memory in Mice</article-title>,&#x0201d; <source>Nature Communications</source>
<volume>12</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>1</fpage>&#x02013;<lpage>20</lpage>, <pub-id pub-id-type="doi">10.1038/s41467-021-26388-4</pub-id>.</mixed-citation></ref><ref id="prp270078-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="prp270078-cit-0017">
<string-name>
<given-names>P. M.</given-names>
<surname>Turunen</surname>
</string-name>, <string-name>
<given-names>M. H.</given-names>
<surname>J&#x000e4;ntti</surname>
</string-name>, and <string-name>
<given-names>J. P.</given-names>
<surname>Kukkonen</surname>
</string-name>, &#x0201c;<article-title>OX 1 Orexin/Hypocretin Receptor Signaling Through Arachidonic Acid and Endocannabinoid Release</article-title>,&#x0201d; <source>Molecular Pharmacology</source>
<volume>82</volume>, no. <issue>2</issue> (<year>2012</year>): <fpage>156</fpage>&#x02013;<lpage>167</lpage>, <pub-id pub-id-type="doi">10.1124/mol.112.078063</pub-id>.<pub-id pub-id-type="pmid">22550093</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="prp270078-cit-0018">
<string-name>
<given-names>S.</given-names>
<surname>Hilairet</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Bouaboula</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Carri&#x000e8;re</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Le Fur</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Casellas</surname>
</string-name>, &#x0201c;<article-title>Hypersensitization of the Orexin 1 Receptor by the CB1 Receptor: Evidence for Cross&#x02010;Talk Blocked by the Specific CB1 Antagonist, SR141716</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>278</volume>, no. <issue>26</issue> (<year>2003</year>): <fpage>23731</fpage>&#x02013;<lpage>23737</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.M212369200</pub-id>.<pub-id pub-id-type="pmid">12690115</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="prp270078-cit-0019">
<string-name>
<given-names>J.</given-names>
<surname>Ellis</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Pediani</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Canals</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Milasta</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Milligan</surname>
</string-name>, &#x0201c;<article-title>Orexin&#x02010;1 Receptor&#x02010;Cannabinoid CB1 Receptor Heterodimerization Results in Both Ligand&#x02010;Dependent and &#x02010;Independent Coordinated Alterations of Receptor Localization and Function</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>281</volume>, no. <issue>50</issue> (<year>2006</year>): <fpage>38812</fpage>&#x02013;<lpage>38824</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.M602494200</pub-id>.<pub-id pub-id-type="pmid">17015451</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="prp270078-cit-0020">
<string-name>
<given-names>Y. C.</given-names>
<surname>Ho</surname>
</string-name>, <string-name>
<given-names>H. J.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>L. W.</given-names>
<surname>Tung</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Activation of Orexin 1 Receptors in the Periaqueductal Gray of Male Rats Leads to Antinociception via Retrograde Endocannabinoid (2&#x02010;Arachidonoylglycerol)&#x02010;induced Disinhibition</article-title>,&#x0201d; <source>Journal of Neuroscience</source>
<volume>31</volume>, no. <issue>41</issue> (<year>2011</year>): <fpage>14600</fpage>&#x02013;<lpage>14610</lpage>, <pub-id pub-id-type="doi">10.1523/JNEUROSCI.2671-11.2011</pub-id>.<pub-id pub-id-type="pmid">21994376</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="prp270078-cit-0021">
<string-name>
<given-names>R.</given-names>
<surname>Imperatore</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Palomba</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Morello</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Formation of OX&#x02010;1R/CB1R Heteromeric Complexes in Embryonic Mouse Hypothalamic Cells: Effect on Intracellular Calcium, 2&#x02010;Arachidonoyl&#x02010;Glycerol Biosynthesis and ERK Phosphorylation</article-title>,&#x0201d; <source>Pharmacological Research</source>
<volume>111</volume> (<year>2016</year>): <fpage>600</fpage>&#x02013;<lpage>609</lpage>, <pub-id pub-id-type="doi">10.1016/j.phrs.2016.07.009</pub-id>.<pub-id pub-id-type="pmid">27436148</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="prp270078-cit-0022">
<string-name>
<given-names>M. H.</given-names>
<surname>J&#x000e4;ntti</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Putula</surname>
</string-name>, <string-name>
<given-names>P. M.</given-names>
<surname>Turunen</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Autocrine Endocannabinoid Signaling Through CB1 Receptors Potentiates OX1 Orexin Receptor Signaling</article-title>,&#x0201d; <source>Molecular Pharmacology</source>
<volume>83</volume>, no. <issue>3</issue> (<year>2013</year>): <fpage>621</fpage>&#x02013;<lpage>632</lpage>, <pub-id pub-id-type="doi">10.1124/mol.112.080523</pub-id>.<pub-id pub-id-type="pmid">23233488</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="prp270078-cit-0023">
<string-name>
<given-names>R. J.</given-names>
<surname>Ward</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Pediani</surname>
</string-name>, and <string-name>
<given-names>G.</given-names>
<surname>Milligan</surname>
</string-name>, &#x0201c;<article-title>Heteromultimerization of Cannabinoid CB1 Receptor and Orexin OX1 Receptor Generates a Unique Complex in Which Both Protomers Are Regulated by Orexin A</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>286</volume>, no. <issue>43</issue> (<year>2011</year>): <fpage>37414</fpage>&#x02013;<lpage>37428</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.M111.287649</pub-id>.<pub-id pub-id-type="pmid">21908614</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="prp270078-cit-0024">
<string-name>
<given-names>I.</given-names>
<surname>Ra&#x000ef;ch</surname>
</string-name>, <string-name>
<given-names>J. B.</given-names>
<surname>Rebassa</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Lillo</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Antagonization of OX1 Receptor Potentiates CB2 Receptor Function in Microglia From APPSw/Ind Mice Model</article-title>,&#x0201d; <source>International Journal of Molecular Sciences</source>
<volume>23</volume>, no. <issue>21</issue> (<year>2022</year>): <elocation-id>12801</elocation-id>, <pub-id pub-id-type="doi">10.3390/ijms232112801</pub-id>.<pub-id pub-id-type="pmid">36361598</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="prp270078-cit-0025">
<string-name>
<given-names>A.</given-names>
<surname>Zagzoog</surname>
</string-name>, <string-name>
<given-names>A. L.</given-names>
<surname>Brandt</surname>
</string-name>, <string-name>
<given-names>T. E.</given-names>
<surname>Black</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Laprairie Assessment of Select Synthetic Cannabinoid Receptor Agonist Bias and Selectivity Between the Type 1 and Type 2 Cannabinoid Receptor</article-title>,&#x0201d; <source>Scientific Reports</source>
<volume>11</volume>, no. <issue>1</issue> (<year>2021</year>): <fpage>1</fpage>&#x02013;<lpage>18</lpage>, <pub-id pub-id-type="doi">10.1038/s41598-021-90167-w</pub-id>.<pub-id pub-id-type="pmid">33414495</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="prp270078-cit-0026">
<string-name>
<given-names>A.</given-names>
<surname>Zagzoog</surname>
</string-name>, <string-name>
<given-names>K. A.</given-names>
<surname>Mohamed</surname>
</string-name>, <string-name>
<given-names>H. J. J. E.</given-names>
<surname>Kim</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>LaprairieIn Vitro and In&#x000a0;Vivo Pharmacological Activity of Minor Cannabinoids Isolated From <italic toggle="yes">Cannabis sativa</italic>
</article-title>,&#x0201d; <source>Scientific Reports</source>
<volume>10</volume>, no. <issue>1</issue> (<year>2020</year>): <fpage>1</fpage>&#x02013;<lpage>13</lpage>, <pub-id pub-id-type="doi">10.1038/s41598-020-77175-y</pub-id>.<pub-id pub-id-type="pmid">31913322</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="prp270078-cit-0027">
<string-name>
<given-names>J.</given-names>
<surname>Schindelin</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Arganda&#x02010;Carreras</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Frise</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Fiji: An Open&#x02010;Source Platform for Biological&#x02010;Image Analysis</article-title>,&#x0201d; <source>Nature Methods</source>
<volume>9</volume>, no. <issue>7</issue> (<year>2012</year>): <fpage>676</fpage>&#x02013;<lpage>682</lpage>, <pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id>.<pub-id pub-id-type="pmid">22743772</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="prp270078-cit-0028">
<string-name>
<given-names>S. D.</given-names>
<surname>Harding</surname>
</string-name>, <string-name>
<given-names>J. L.</given-names>
<surname>Sharman</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Faccenda</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The IUPHAR/BPS Guide to PHARMACOLOGY in 2019: Updates and Expansion to Encompass the New Guide to Immunopharmacology</article-title>,&#x0201d; <source>Nucleic Acids Research</source>
<volume>46</volume>, no. <issue>D1</issue> (<year>2017</year>): <fpage>D1091</fpage>&#x02013;<lpage>D1106</lpage>, <pub-id pub-id-type="doi">10.1093/nar/gkx1121</pub-id>.</mixed-citation></ref><ref id="prp270078-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="prp270078-cit-0029">
<string-name>
<given-names>S. P. H.</given-names>
<surname>Alexander</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Christopoulos</surname>
</string-name>, <string-name>
<given-names>A. P.</given-names>
<surname>Davenport</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>The Concise Guide to Pharmacology 2023/24: G Protein&#x02010;Coupled Receptors</article-title>,&#x0201d; <source>British Journal of Pharmacology</source>
<volume>180</volume>, no. <issue>Suppl 2</issue> (<year>2023</year>): <elocation-id>S23S144S2</elocation-id>, <pub-id pub-id-type="doi">10.1111/bph.16177</pub-id>.</mixed-citation></ref><ref id="prp270078-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="prp270078-cit-0030">
<string-name>
<given-names>N. C.</given-names>
<surname>Dale</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Hoyer</surname>
</string-name>, <string-name>
<given-names>L. H.</given-names>
<surname>Jacobson</surname>
</string-name>, <string-name>
<given-names>K. D. G.</given-names>
<surname>Pfleger</surname>
</string-name>, and <string-name>
<given-names>E. K. M.</given-names>
<surname>Johnstone</surname>
</string-name>, &#x0201c;<article-title>Orexin Signaling: A Complex, Multifacted Process</article-title>,&#x0201d; <source>Frontiers in Cellular Neuroscience</source>
<volume>16</volume>, no. <issue>1</issue> (<year>2022</year>): <fpage>812359</fpage>, <pub-id pub-id-type="doi">10.3389/fncl.2022.812359</pub-id>.<pub-id pub-id-type="pmid">35496914</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="prp270078-cit-0031">
<string-name>
<given-names>M. D.</given-names>
<surname>Thompson</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Sakurai</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Rainero</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Maj</surname>
</string-name>, and <string-name>
<given-names>J. P.</given-names>
<surname>Kukkonen</surname>
</string-name>, &#x0201c;<article-title>Orexin Receptor Multimerization Versus Functional Interactions: Neuropharmacological Implications for Opioid and Cannabinoid Signalling and Pharmacogenetics</article-title>,&#x0201d; <source>Pharmaceuticals</source>
<volume>10</volume>, no. <issue>4</issue> (<year>2017</year>): <fpage>1</fpage>&#x02013;<lpage>20</lpage>, <pub-id pub-id-type="doi">10.3390/ph10040079</pub-id>.</mixed-citation></ref><ref id="prp270078-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="prp270078-cit-0032">
<string-name>
<given-names>P.</given-names>
<surname>Carriba</surname>
</string-name>, <string-name>
<given-names>O.</given-names>
<surname>Ortiz</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Patkar</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes That Mediate the Motor Effects of Cannabinoids</article-title>,&#x0201d; <source>Neuropsychopharmacology</source>
<volume>32</volume>, no. <issue>11</issue> (<year>2007</year>): <fpage>2249</fpage>&#x02013;<lpage>2259</lpage>, <pub-id pub-id-type="doi">10.1038/sj.npp.1301375</pub-id>.<pub-id pub-id-type="pmid">17356572</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="prp270078-cit-0033">
<string-name>
<given-names>M.</given-names>
<surname>Hojo</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Sudo</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Ando</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>&#x003bc;&#x02010;Opioid Receptor Forms a Functional Heterodimer With Cannabinoid CB1 Receptor: Electrophysiological and Fret Assay Analysis</article-title>,&#x0201d; <source>Journal of Pharmacological Sciences</source>
<volume>108</volume>, no. <issue>3</issue> (<year>2008</year>): <fpage>308</fpage>&#x02013;<lpage>319</lpage>, <pub-id pub-id-type="doi">10.1254/jphs.08244FP</pub-id>.<pub-id pub-id-type="pmid">19008645</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="prp270078-cit-0034">
<string-name>
<given-names>J.</given-names>
<surname>Kargl</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Balenga</surname>
</string-name>, <string-name>
<given-names>G. P.</given-names>
<surname>Parzmair</surname>
</string-name>, <string-name>
<given-names>A. J.</given-names>
<surname>Brown</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Heinemann</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Waldhoer</surname>
</string-name>, &#x0201c;<article-title>The Cannabinoid Receptor CB1 Modulates the Signaling Properties of the Lysophosphatidylinositol Receptor GPR55</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>287</volume>, no. <issue>53</issue> (<year>2012</year>): <fpage>44234</fpage>&#x02013;<lpage>44248</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.M112.364109</pub-id>.<pub-id pub-id-type="pmid">23161546</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="prp270078-cit-0035">
<string-name>
<given-names>S.</given-names>
<surname>Zou</surname>
</string-name>, <string-name>
<given-names>R. K.</given-names>
<surname>Somvanshi</surname>
</string-name>, and <string-name>
<given-names>U.</given-names>
<surname>Kumar</surname>
</string-name>, &#x0201c;<article-title>Somatostatin Receptor 5 Is a Prominent Regulator of Signaling Pathways in Cells With Coexpression of Cannabinoid Receptors 1</article-title>,&#x0201d; <source>Neuroscience</source>
<volume>340</volume> (<year>2017</year>): <fpage>218</fpage>&#x02013;<lpage>231</lpage>, <pub-id pub-id-type="doi">10.1016/j.neuroscience.2016.10.056</pub-id>.<pub-id pub-id-type="pmid">27984180</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="prp270078-cit-0036">
<string-name>
<given-names>X.</given-names>
<surname>Vi&#x000f1;als</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Moreno</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Lanfumey</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Cognitive Impairment Induced by delta9&#x02010; Tetrahydrocannabinol Occurs Through Heteromers Between Cannabinoid CB1 and Serotonin 5&#x02010;HT2A Receptors</article-title>,&#x0201d; <source>PLoS Biology</source>
<volume>13</volume>, no. <issue>7</issue> (<year>2015</year>): <fpage>1</fpage>&#x02013;<lpage>40</lpage>, <pub-id pub-id-type="doi">10.1371/journal.pbio.1002194</pub-id>.</mixed-citation></ref><ref id="prp270078-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="prp270078-cit-0037">
<string-name>
<given-names>C. S.</given-names>
<surname>Kearn</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Blake&#x02010;Palmer</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Daniel</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Mackie</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Glass</surname>
</string-name>, &#x0201c;<article-title>Concurrent Stimulation of Cannabinoid CB1 and Dopamine D2 Receptors Enhances Heterodimer Formation: A Mechanism for Receptor Cross&#x02010;Talk?</article-title>,&#x0201d; <source>Molecular Pharmacology</source>
<volume>67</volume>, no. <issue>5</issue> (<year>2005</year>): <fpage>1697</fpage>&#x02013;<lpage>1704</lpage>, <pub-id pub-id-type="doi">10.1124/mol.104.006882</pub-id>.<pub-id pub-id-type="pmid">15710746</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="prp270078-cit-0038">
<string-name>
<given-names>P.</given-names>
<surname>Morales</surname>
</string-name> and <string-name>
<given-names>P. H.</given-names>
<surname>Reggio</surname>
</string-name>, &#x0201c;<article-title>An Update on Non&#x02010;CB 1, Non&#x02010;CB 2 Cannabinoid Related G&#x02010;Protein&#x02010;Coupled Receptors</article-title>,&#x0201d; <source>Cannabis and Cannabinoid Research</source>
<volume>2</volume>, no. <issue>1</issue> (<year>2017</year>): <fpage>265</fpage>&#x02013;<lpage>273</lpage>, <pub-id pub-id-type="doi">10.1089/can.2017.0036</pub-id>.<pub-id pub-id-type="pmid">29098189</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="prp270078-cit-0039">
<string-name>
<given-names>E.</given-names>
<surname>Moreno</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Andradas</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Medrano</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Targeting CB2&#x02010;GPR55 Receptor Heteromers Modulates Cancer Cell Signaling</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>289</volume>, no. <issue>32</issue> (<year>2014</year>): <fpage>21960</fpage>&#x02013;<lpage>21972</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.M114.561761</pub-id>.<pub-id pub-id-type="pmid">24942731</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="prp270078-cit-0040">
<string-name>
<given-names>C. J.</given-names>
<surname>Coke</surname>
</string-name>, <string-name>
<given-names>K. A.</given-names>
<surname>Scarlett</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Chetram</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Simultaneous Activation of Induced Heterodimerization Between CXCR4 Chemokine Receptor and Cannabinoid Receptor 2 (CB2) Reveals a Mechanism for Regulation of Tumor Progression</article-title>,&#x0201d; <source>Journal of Biological Chemistry</source>
<volume>291</volume>, no. <issue>19</issue> (<year>2016</year>): <fpage>9991</fpage>&#x02013;<lpage>10005</lpage>, <pub-id pub-id-type="doi">10.1074/jbc.M115.712661</pub-id>.<pub-id pub-id-type="pmid">26841863</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="prp270078-cit-0041">
<string-name>
<given-names>A.</given-names>
<surname>Dhopeshwarkar</surname>
</string-name> and <string-name>
<given-names>K.</given-names>
<surname>Mackie</surname>
</string-name>, &#x0201c;<article-title>CB2 Cannabinoid Receptors as a Therapeutic Target&#x02014;What Does the Future Hold?</article-title>,&#x0201d; <source>Molecular Pharmacology</source>
<volume>86</volume>, no. <issue>4</issue> (<year>2014</year>): <fpage>430</fpage>&#x02013;<lpage>437</lpage>.<pub-id pub-id-type="pmid">25106425</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="prp270078-cit-0042">
<string-name>
<given-names>S.</given-names>
<surname>Ferr&#x000e9;</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Baler</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Bouvier</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>Building a New Conceptual Framework for Receptor Heteromers</article-title>,&#x0201d; <source>Nature Chemical Biology</source>
<volume>5</volume>, no. <issue>3</issue> (<year>2009</year>): <fpage>131</fpage>&#x02013;<lpage>134</lpage>, <pub-id pub-id-type="doi">10.1038/nchembio0309-131</pub-id>.<pub-id pub-id-type="pmid">19219011</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="prp270078-cit-0043">
<string-name>
<given-names>B. B.</given-names>
<surname>Yao</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Mukherjee</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Fan</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>In Vitro Pharmacological Characterization of AM1241: A Protean Agonist at the Cannabinoid CB 2 Receptor?</article-title>,&#x0201d; <source>British Journal of Pharmacology</source>
<volume>149</volume>, no. <issue>2</issue> (<year>2006</year>): <fpage>145</fpage>&#x02013;<lpage>154</lpage>, <pub-id pub-id-type="doi">10.1038/sj.bjp.0706838</pub-id>.<pub-id pub-id-type="pmid">16894349</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="prp270078-cit-0044">
<string-name>
<given-names>A.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Huang</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ahn</surname>
</string-name>, and <string-name>
<given-names>R. J.</given-names>
<surname>Lefkowitz</surname>
</string-name>, &#x0201c;<article-title>Loss of Biased Signaling at a G Proteincoupled Receptor in Overexpressed Systems</article-title>,&#x0201d; <source>PLoS One</source>
<volume>18</volume>, no. <issue>3</issue> (<year>2023</year>): <elocation-id>e0283477</elocation-id>, <pub-id pub-id-type="doi">10.1371/journal.pone.0283477</pub-id>.<pub-id pub-id-type="pmid">36961836</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="prp270078-cit-0045">
<string-name>
<given-names>M. H.</given-names>
<surname>J&#x000e4;ntti</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Mandrika</surname>
</string-name>, and <string-name>
<given-names>J. P.</given-names>
<surname>Kukkonen</surname>
</string-name>, &#x0201c;<article-title>Human Orexin/Hypocretin Receptors Form Constitutive Homo&#x02010; and Heteromeric Complexes With Each Other and With Human CB1 Cannabinoid Receptors</article-title>,&#x0201d; <source>Biochemical and Biophysical Research Communications</source>
<volume>445</volume>, no. <issue>2</issue> (<year>2014</year>): <fpage>486</fpage>&#x02013;<lpage>490</lpage>, <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.02.026</pub-id>.<pub-id pub-id-type="pmid">24530395</pub-id>
</mixed-citation></ref><ref id="prp270078-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="prp270078-cit-0046">
<string-name>
<given-names>H. J. J.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Zagzoog</surname>
</string-name>, <string-name>
<given-names>A. M.</given-names>
<surname>Smolyakova</surname>
</string-name>, et&#x000a0;al., &#x0201c;<article-title>In Vivo Evidence for Brain Region&#x02010;Specific Molecular Interactions Between Cannabinoid and Orexin Receptors</article-title>,&#x0201d; <source>Frontiers in Neuroscience</source>
<volume>15</volume> (<year>2021</year>): <fpage>1</fpage>&#x02013;<lpage>16</lpage>, <pub-id pub-id-type="doi">10.3389/fnins.2021.790546</pub-id>.</mixed-citation></ref><ref id="prp270078-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="prp270078-cit-0047">
<string-name>
<given-names>F.</given-names>
<surname>Berrendero</surname>
</string-name>, <string-name>
<given-names>&#x000c1;.</given-names>
<surname>Flores</surname>
</string-name>, and <string-name>
<given-names>P.</given-names>
<surname>Robledo</surname>
</string-name>, &#x0201c;<article-title>When Orexins Meet Cannabinoids: Bidirectional Functional Interactions</article-title>,&#x0201d; <source>Biochemical Pharmacology</source>
<volume>157</volume> (<year>2018</year>): <fpage>43</fpage>&#x02013;<lpage>50</lpage>, <pub-id pub-id-type="doi">10.1016/j.bcp.2018.08.040</pub-id>.<pub-id pub-id-type="pmid">30171834</pub-id>
</mixed-citation></ref></ref-list></back></article>